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ABSTRACT 
This dissertation applied molecular epidemiology to address the relationship between the 
environment and cancer. The World Health Organization has identified cancer as the leading 
cause of death worldwide, and according to the International Agency for Research on Cancer, the 
global burden of cancer lies primarily in low- and middle-income countries (LMICs), and this 
disparity will become more extreme by 2035. Many LMICs are undergoing an epidemiologic 
transition involving a shift in health burden from infectious to chronic diseases. Because we 
know that the majority of cancers are sporadic and caused by a combination of genetic and 
environmental factors, it is crucial to understand the effects of the surrounding environment on 
cancer incidence, induction and outcomes. 
The first objective of this dissertation was to characterize female breast cancer incidence 
trends in southern Thailand. Thailand is a LMIC in an epidemiologic transition. Women are 
adopting lifestyle changes that affect their risk of developing breast cancer, including reduced 
parity, later age at first birth and fewer years of breastfeeding. Incidence rates of breast cancer 
increased by almost 300% from 1990 to 2010. Both period and birth cohort effects played a role 
in shaping the increase in incidence. Three distinct incidence projection methods consistently 
suggested that incidence rates will continue to increase in the future with incidence for women 
age 50 and above increasing at a higher rate than for women below 50. This is the first study to 
utilize Thai cancer registry data in identifying relevant trends in a region-specific manner. The 
findings from this study identify opportunities for breast cancer prevention and
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future research both by identifying priorities for screening and developing hypotheses for 
population-based studies. 
Cadmium is a Class 1 carcinogen (IARC), however its mechanism of toxicity is 
unknown. My second objective was to determine epigenetic changes associated with this 
exposure. There are significant areas of environmental cadmium exposure in Thailand. 
Environmental cadmium exposure is associated with specific DNA methylation, and this 
relationship depended on the gender of the individual. Identification of these biomarkers of 
cadmium in a human population is a logical first step to identifying the mechanism of 
carcinogenesis.  
Epigenetic changes are a hallmark of cancers, but the relationship between environmental 
and epidemiologic factors and these changes is not well understood.  Tobacco, alcohol and 
human papillomavirus are known etiologic environmental factors of head and neck cancer. 
Novel relationships between methylation markers, survival and recurrence were identified in a 
large cohort of HNC patients. These associations differed based upon etiologic environmental 
factors. Identification of these significant epigenetic markers should open new horizons for 
interventions directed at reversible gene alterations and new therapeutic targets.  
Overall, this research provides an understanding of the environmental contribution to 
cancer incidence, pathogenesis and prognosis. It offers a basis for future studies aimed at 
developing targeted interventions to address the rise in cancer incidence in Thailand, toxicity of 
environmental exposures and determining individualized treatment therapies to promote patient 
survival. 
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CHAPTER 1 
Introduction 
 
Theme 
Cancer is a leading cause of death worldwide, with 14.1 million new cancer and 8.2 
million deaths in 20121. Approximately 19% of cancer cases worldwide are attributed to 
environmental factors2. The expected increase in global population is projected to shift 60-70% 
of the global cancer burden on low- and middle-income countries, where life expectancy is 
increasing with a concurrent decrease in mortality from infectious disease. In high-income 
countries, cancer mortality has stayed stable1. To address these issues, the theme of this 
dissertation is to characterize epidemiologic and molecular factors in cancer incidence, 
pathogenesis, and prognosis.  
There is a significant environmental contribution to the development of cancer. Cancer 
rates vary substantially across countries4, both by and within cancer site.  While some variability 
may be due to genetic differences between populations, the majority of human cancers do not 
show simple patterns of inheritance5, indicating the important role of environmental and lifestyle 
factor. This is illustrated by cancer incidence patterns from geographic variations and of migrant 
populations, which change to reflect rates of the adoptive country after one or two generations. 
For example, Japanese immigrants in the US had increased incidences of cancers of the breast, 
uterine corpus, and ovary for woman and prostate for men6 similar to those rates in the US.  
Similarly, Chinese populations who generally had low incidence rates of prostate and breast 
cancers in China saw increased rates of these upon migration to the US7.  Shifts in incidence 
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rates have also been observed in countries that have undergone rapid, substantial, economic 
development. For example, colorectal cancer rates of younger Japanese generations, born after 
1930, mimic those of their US Caucasian counterparts8. Therefore, as LMICs undergo 
epidemiologic transitions that drive lifestyle changes, we can expect to see significant increases 
in cancer incidence rates that have previously been associated with developed countries, such as 
breast, colon, and prostate cancers.  
 Establishment of cancer registries has been a critical first step in public health planning, 
cancer prevention strategies, health care planning and patient care10 11. Registries collect 
information on age, gender, cancer site, and stage of disease, for all cancer cases in a defined 
geographical area10. These data are used in descriptive studies by providing statistics that can be 
used to identify patterns and variations across gender and age groups for specific cancer sites. 
Understanding patterns of cancer trends is important in generating etiological hypotheses that 
focus future studies and strategies of prevention, mechanism or treatment.. Characterization of 
these population incidence trends is necessary to evaluate the growing burden of cancer in 
LMICs.  
The basic principles of multistage carcinogenesis and tumor biology are that cancer is a 
multistage process that involves sequential dysregulation of cellular pathways. These key 
features of carcinogenesis arise from the interaction of genetic alterations with acquired 
epigenetic abnormalities. Epigenetics is the study of heritable changes in gene expression that do 
not involve changes to the DNA sequence16. All cells in an individual are genetically identical 
but become structurally and functionally diverse due to differential expression of genes. 
Epigenetic mechanisms, such as DNA methylation, histone/chromatin modification, and non-
coding RNAs interpret genetic code and regulate gene expression to promote development and 
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cell differentiation17-21. Therefore, the epigenome could be considered to be a link between 
genotype and phenotype22.  
DNA methylation is the most extensively characterized epigenetic modification. It 
involves the methylation of the fifth carbon of a cytosine nucleotide to create 5-methylcytosine 
(5mC). The methyl group of 5mC lies in the major groove of the double helix and can interfere 
with transcription factor binding to prevent gene expression23-25. Cytosine pairs with guanine by 
means of a phosphate group, and this dinucleotide (CpG) has been a major focus of epigenetic 
research because of its capacity to directly silence gene expression, particularly with respect to 
tumor-suppressor genes in carcinogenesis. CpG sites are unevenly distributed throughout the 
genome, concentrating in repetitive sequences such as tandem and interspersed repeats, distal 
gene regulatory regions, and at 5’ promoter ends of genes, called CpG islands26, 27. CpG islands 
occupy approximately 60% of human gene promoters, most of which are constitutively 
expressed genes, such as housekeeping and regulatory genes28. A CpG island is generally 
defined as a 1000-kb stretch of DNA with GC content greater than 50%. The normal 
hypomethylated pattern of CpG islands is found to be consistent across various types of somatic 
tissues despite tissue-specific differences, illustrating that DNA methylation of these islands is 
not used as a regulatory mechanism of gene expression23, 27, 28. Therefore, when a CpG island 
becomes aberrantly methylated, it can have detrimental effects by stably silencing the associated 
gene29. The cancer cell genome is characterized by hypermethylation of CpG islands in promoter 
regions27, 30, 31. Hypermethylation in these regions promotes the progression of tumorigenesis by 
silencing tumor-suppressor genes32-34. Suppression of p16, a cell-cycle regulator, occurs in 
essentially all common human cancers35. Inactivating these tumor suppressors directly promotes 
tumorigenesis due to lack of control over cellular processes. In addition to tumor-suppressor 
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genes, hypermethylation of other classes of genes such as DNA repair genes and transcription 
factors can indirectly lead to tumorigenesis through silencing of further downstream targets or 
accumulation of genetic errors36, 37. Therefore, hypermethylation of CpG islands in cancers can 
affect multiple pathways to promote carcinogenesis. Although it may appear that 
hypomethylation and hypermethylation in cancer are opposing forces, the patterns usually 
coexist within the same tumor, though in different genomic regions. Further, the epigenetic 
abnormalities that occur because of hypo- and hypermethylation can interact in various ways to 
produce distinct subtypes of cancer, contributing to the complexity of the cancer cell epigenome.  
Just as the epigenome is influenced by intrinsic signals, it is also shaped by external 
environmental stimuli. DNA methylation changes have been associated with a variety of 
environmental factors, including tobacco smoke, sunlight, air pollution, asbestos, physical 
activity, diet and alcohol consumption17, 38-41. A pivotal study analyzing epigenetic changes in 
monozygotic twins found that genetically identical twins were almost indistinguishable in terms 
of their epigenome in early years of life; however older monozygotic twins had remarkably 
different patterns of DNA methylation and, consequently, gene expression profiles42, suggesting 
that epigenetic changes are influenced by extrinsic factors encountered throughout life and can 
explain phenotypic differences between monozygotic twins. A separate study examined 
monozygotic twins longitudinally and found that individual differences in methylation were not 
stable over time, suggesting that environmental influences account for these changes 
differentially across the genome43. DNA methylation profiles occur in response to environmental 
stimuli and therefore, provide information about biological predisposition for adverse health 
outcomes due to environmental exposures. DNA methylation tends to precede chromosomal 
instability and genetic alterations, may be reversible and is involved in early and precancerous 
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stages44-47.  Additionally, these patterns are stable but not irreversible and remain flexible as the 
surrounding environment changes, making them desirable candidates for intermediate and 
prognostic biomarkers. 
 
Specific Aims 
Identification of human carcinogens is difficult when exposures are diffuse and chronic, 
as they tend to be in environmental exposures.  The projected increase in cancer rates attributable 
to environmental factors highlights the need to determine novel biomarkers that predict risk of 
developing disease in response to exposures and to monitor disease progression. DNA 
methylation is a critical epigenetic mechanism incorporating the genome with the environment to 
regulate phenotype plasticity.  It can control gene expression in a way that is stably propagated 
over multiple cell divisions, but is also flexible enough to respond to environmental influences. 
This intermediate position between stability and plasticity renders epigenetic information highly 
useful as biomarkers for monitoring cellular states that offer insight into potential mechanisms 
between exposure and disease.  
 
Aim 1. Identify and analyze population incidence trends of pre- and post-menopausal female 
breast cancer in Southern Thailand and project incidence rates into the future using 
mathematical modeling. 
As outlined above, LMICs are expected to exhibit an increase in cancer incidence rates as 
they undergo lifestyle changes to mimic those of developed countries. It is necessary to 
characterize these incidence trends to reveal changes in population rates. Therefore, in this aim, 
female breast cancer rates in southern Thailand are analyzed using various vigorous statistical 
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methods for comparative analyses and projected into the future using mathematical modeling.  
The hypotheses examined in this aim include: 
 
Hypothesis 1.1: Epidemiologic trends are influenced by a combination of period and 
cohort effects due to the epidemiologic transition of the country. 
Hypothesis 1.2: Breast cancer incidence will continue to increase in the future, 
particularly in postmenopausal women. 
 
Aim 2. Quantify epigenetic variation of candidate genes in a population of control and cadmium 
exposed subjects living in and around the Mae Sot District of Thailand and determine their 
association with urinary cadmium levels and renal biomarkers. 
Biomarkers of exposure are necessary to understand the biological changes that occur in 
response to environmental exposure. A sub-district in northern Thailand consisting of thirteen 
villages is highly exposed to environmental cadmium due to runoff from a long-standing zinc 
mine. Cadmium is listed as a carcinogen based on studies conducted in occupational settings 
with acute exposures. However, environmental cadmium exposures are chronically low and there 
is limited evidence as to the mechanism by which cadmium exerts its toxic effects in non-
occupational exposures. This aim focuses on identification of biomarkers of exposure and 
investigates the following hypotheses: 
 
Hypothesis 2.1: DNA methylation markers are associated with cadmium exposure as 
measured by urinary cadmium levels.  
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Hypothesis 2.2: DNA methylation markers are associated with markers of adverse health 
outcomes. 
 
Aim 3: Identify whether the association between exposure to viral/chemical carcinogens and 
tumor recurrence or survival is mediated through epigenetic mechanisms in head and neck 
cancer patients. 
Biomarkers of cancer are used to monitor disease progression, inform prognosis and 
guide therapy.  In head and neck squamous cell carcinoma, patient characteristics such as, 
tobacco and alcohol use, human papillomavirus, patient age, comorbidity status and gender are 
generally used to identify high risk groups. However tumor heterogeneity makes it difficult to 
speculate disease trajectory, highlighting a need to identify biomarkers that encompass 
population characteristics, respond to environmental stimuli and provide information about 
tumor biology. The following hypotheses addressed the identification of these markers in this 
aim: 
Hypothesis 3.1: Tumor DNA methylation profiles are associated with epidemiologic and 
clinicopathologic characteristics. 
Hypothesis 3.2: DNA methylation profiles predict patient survival and recurrence from 
head and neck squamous cell carcinoma. 
 
Conceptual Framework 
Figure 1.2 outlines the conceptual framework for this dissertation research. Population-
based epidemiology is needed to characterize cancer rates that are important for specific 
populations. Breast cancer incidence rates in southern Thailand will be characterized in Specific 
Aim 1. Once a cancer is found to affect a specific population, it is necessary to understand how 
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the environment affects induction of cancer using molecular events. The association between 
cadmium exposure and carcinogenesis will be investigated in Specific Aim 2. The environment 
can also play a role in prognosis in patients with cancer as well. The relationship between the 
environment and prognosis of head and neck squamous cell carcinoma will be explored in 
Specific Aim 3.  
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Figure 1.1 Global burden of cancer by year 2035.  
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Figure 1.2. Conceptual framework.  
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CHAPTER 2 
Escalating burden of breast cancer in southern Thailand: analysis of 
1990-2010 incidence and prediction of future trends 
 
ABSTRACT 
Background: Thailand is undergoing an epidemiologic transition, with decreasing incidence of 
infectious diseases and increasing rates of chronic conditions, including cancer.   Breast cancer 
has the highest incidence rates among females both in the southern region of Thailand and 
throughout Thailand. However, there is a lack of research on the epidemiology of this and other 
cancers.  
Methods: Here we use cancer incidence data from the Songkhla Cancer Registry to characterize 
and analyze the incidence of breast cancer in Southern Thailand. We use joinpoint analysis, age-
period-cohort models and nordpred analysis to investigate the incidence of breast cancer in 
Southern Thailand from 1990-2010 and project future trends from 2010-2029.  
Results: We found that age-adjusted breast cancer incidence rates in Southern Thailand increased 
by almost 300% from 1990 to 2010 going from 10.0 to 27.8 cases per 100,000 person-years. 
Both period and cohort effects played a role in shaping the increase in incidence. Three distinct 
incidence projection methods consistently suggested that incidence rates will continue to 
increase in the future with incidence for women age 50 and above increasing at a higher rate than 
for women below 50.  
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Conclusions: To date, this is the first study to examine Thai breast cancer incidence from a 
regional registry. This study provides a basis for future planning strategies in breast cancer 
prevention and to guide hypotheses for population-based epidemiologic research in Thailand. 
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INTRODUCTION 
Thailand is undergoing an epidemiologic transition, with decreasing rates of mortality 
due to infectious diseases and increasing rates of chronic conditions, including cancer. 
Worldwide cancer incidence is projected to rise 70% by the year 2030, with the largest burden 
on low- and middle – income countries (LMICs)1. Breast cancer poses a particular problem over 
the next decades as LMICs are increasingly adopting characteristics of a Western lifestyle. There 
is a strong association between Western lifestyle factors, such as diet and parity, and the 
incidence of breast cancer2-5. Since mammographic screening is often not available in LMICs, 
accurate incidence predictions are crucial to target resources to prevent and control breast cancer. 
Breast cancer incidence rates are increasing throughout Thailand6. From 1998-2000, the 
age-standardized incidence rate (ASR) was 20.5 cases and increased to 30.7 cases per 100,000 
person-years in 2008 1, 7. However, the epidemiologic basis of breast cancer in Thailand is not 
well characterized. The regions of Thailand vary dramatically in terms of population 
characteristics, risk factor exposures, and incidence rates6. Southern Thailand consists of a 
population of unique ethnic and cultural make-up. The Thai National Statistics office estimates 
that Muslims make up approximately 30% of the population of southern Thailand8. Muslims in 
the Songkhla province are nonetheless predominantly of Thai ethnicity. This results in a unique 
population since religiosity is known to be correlated with distinct lifestyle characteristics and 
potentially distinct risks for cancer and other diseases.  
Registry data have been used in other LMICs to identify cancer trends, inform resource 
planning and guide hypotheses for population-based epidemiologic research9-13. A cancer 
registry was established in the Songkhla Province in 1989 to characterize the cancer incidence in 
southern Thailand. We investigated incidence rates of female breast cancer data from the 
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Songkhla registry from 1990-2010 using joinpoint regression and age-period-cohort models.  
The goal of these analyses was to characterize, for the first time, the breast cancer incidence 
trends in the province by calendar year, birth-cohort, age of diagnosis, and to project female 
breast cancer rates in southern Thailand to 2029 (Thai calendar: 2572), for all women and 
separated by pre and post-menopausal women. Each of the main regions of Thailand differ in 
their cancer incidence profiles and therefore, it is essential to analyze incidence rates by region6, 
12. This is the first study to utilize Thai cancer registry data in identifying relevant trends in a 
region-specific manner. Our analyses highlight the utility of carefully collected cancer 
surveillance data in LMICs, and identify opportunities for breast cancer prevention and future 
research. 
 
METHODS 
Region 
Songkhla, Thailand is a southern province occupying an area of 7,393 square kilometers on the 
eastern side of the Malaysian Peninsula (Figure 2.1).  Muslims make up approximately 30% of 
the population of southern Thailand over 15 years of age 8. The average life expectancy in the 
Thailand for females is 77.5 years14.  
 
Cancer Registry 
The Songkhla Registry covers sixteen districts in southern Thailand. The population of southern 
Thailand at the 2010 census was 8.9 million people of which 4.4 million were females 15. This 
registry actively compiles cancer cases from 23 sources including community hospitals, private 
hospitals, and the population registration office. The number of undetected cases is difficult to 
19	  
	  
estimate due to remote villages with limited access to health facilities and the use of traditional 
Thai medicine in lieu of health care services.  
Female breast cancer cases were extracted from the Songkhla Cancer Registry from 1990 
through 2010 using ICD-10 codes C50.X.  Information included age at diagnosis, date of 
diagnosis and stage at diagnosis. In situ cases were excluded. Person-years were calculated from 
census data15-17. Age-specific incidence rates were calculated for eighteen age groups (0-4, 5-9, 
…, 80-84, and ≥85) and twenty-one calendar periods from 1990 to 2010 (1-year intervals). This 
stratification resulted in data for 90 single-year birth cohorts from 1902 through 1992.  
 
Trend Analysis 
We standardized age-adjusted breast cancer incidence rates in Songkhla, Thailand from 1990-
2010 to the World Health Organization (WHO) world population18, 19. We then evaluated trends 
in incidence using the Joinpoint-Regression Program version 4.0.420.  Joinpoint regression 
identifies statistically significant trend change points (joinpoints) and the rate of change (annual 
percent change) in each trend segment using a Monte Carlo permutation method. Analyses were 
conducted for all females, and then for females younger than 50, and females 50 years old or 
older to determine differences in incidence trends above and below the mean age of 
menopause21, 22. 
 
Age-Period-Cohort Models 
To investigate the effects of age, calendar year, and birth-cohort on the incidence of breast 
cancer, we fit age-period cohort models to the incidence rates. Age-specific incidence rates were 
calculated for 5-year age groups. We used the “classical” method of analysis, which fits a log-
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linear model with a Poisson distribution to the observed data to estimate age, period, and cohort 
effects in a multiplicative APC model as follows: 
 
logλa,p = f(a) + g(p) + h(c) 
 
where the expected log-incidence rates λa,p is assumed to be equal to a linear combination of 
effects that adjust for age a, period p, and birth-cohort c, with c=p-a. To address the well-known 
non-identifiability problem of APC models, we fit two-effects models (Age-Period and Age-
Cohort) and then fit the remaining effect (cohort or period) to the respective model’s residuals 
using natural splines to reduce random variation 23. These are referred to as the AP-C and AC-P 
models. 
  
Comparative Modeling for Prediction of Incidence Rates 
We used three independent methods to project the incidence rates of breast cancer in the 
Songkhla province; joinpoint, nordpred and age-period-cohort model projections.  
 
Joinpoint. Each best-fit joinpoint model was separated into its linear and residual components. 
The residuals described the curvature while the linear component illustrated the secular drift of 
the trend. Natural spline models were fit to each separate component and extrapolated out to 
2029. To reduce the effect of drift in projected incidence rates, the linear component of the trend 
was attenuated by 5% each year from 2015-2019, 10% each year from 2020-2024, and 15% each 
year from 2025-2029.  Residual and linear components were then added to give total age-
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adjusted incidence rates with linear attenuation. Separate projections were made for all females, 
females below age 50 and female at or above age 50.    
 
Nordpred. We used the nordpred R-package to project the breast cancer incidence in Songkhla.  
Nordpred fit an APC model to the data and then calculated world-standardized incidence rates 
for eighteen age groups (from 0-4 to ≥85, 5-year intervals) and 5-year interval periods (1990-
1994,…, 2004-2009). Trends based upon all of the observed data were then extrapolated out to 
four 5-yr periods, ending in 2029. To avoid overestimation of cases from the multiplicative 
model, a power function in Nordpred was used to attenuate the linear drift by 25%, 50%, and 
75%, respectively, for the second (2015-2019), third (2020-2024) and fourth (2025-2029) 5-year 
projection periods.  
 
AP-C. The third prediction approach used a spline model fit to the AP-C model period effect 
estimates across all 18 age groups. Similar to the joinpoint projections, the linear and residual 
components of the period effects were separated out and projected individually to 2029. The 
linear component of each model was attenuated as done in joinpoint. Residual and attenuated 
linear components were added to yield period effects to year 2029. Incidence rates from 2010-
2029 were calculated using the AP-C model age-effects, and the projected period effects, as well 
as projected population counts by age15-17, 24. Models were run with the same method for all 
females, females under age 50 and females at or above age 50.  
 
AC-P. The fourth prediction model used a spline model fit to the estimated cohort effect 
estimates from the AC-P model. Linear and residual components were separated and projected to 
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2029, and incidence rates were calculated as described above. In all cases, the estimated period 
effects of the AC-P models were almost identical to 1. We therefore projected the period effects 
for these models as 1, and applied the corresponding attenuation effects as was done for joinpoint 
and AP-C model projections.  
 
Joinpoint Regression Program and the R-statistical software were used for trend analysis and 
prediction (Epi 1.1.44 and NORDPRED, R version 3.0.1)23, 25, 26. 
 
RESULTS 
There were 2,545 cases of total female breast cancer diagnosed in Songkhla Province from 1990-
2010. Of these, 1,280 occurred in females under the age of 50 and 1,265 cases in females over 
the age of 50. Stage distribution by each age group is shown (Figure 2.2). The underlying trends 
in stage classification for both age groups show an increasing percentage of cases across periods 
for local and regional cancers and a decrease in unknown cancers. Because this decrease in 
unknown cases across time would create bias any trend analysis, stage was not used as a 
parameter in our analyses of female breast cancer rates in Songkhla. 
 
Joinpoint Analysis 
Breast cancer incidence rates increased from an age-standardized rate (ASR) of 10.0 in 
1990 to an ASR of 27.8 cases per 100,000 person-years in 2010, an increase of 4.1% per year 
(Figure 2.3, Table 2.1). Overall, the incidence rate of female breast cancer increased at an annual 
percentage change (APC) of 1.55% from 1990-1997 and then increased by 15.08% per year from 
1998-2000, although due to the low number of cases and the short period this trend was not 
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statistically significant. From 2001-2010, there was a significant 1.90% increase per year (Figure 
2.3a.). Women under the age of 50 had a significant increase in incidence from 1990-1995 (APC: 
10.73%) (Figure 2.3b), but the overall trend of incidence rates was low compared to women over 
50. Breast cancer incidence for this group increased from an ASR of 23.98 cases in 1990 to 
74.40 cases per 100,000 in 2010, a 4.63% increase per year (p-value<0.05) (Figure 2.3c).  
Comparison of both age group show the increase in incidence trend for all females was primarily 
driven by incidence rates of women over the age of 50 (Figure 2.3d). 
 
Age-Period-Cohort  Analyses 
Descriptive Analysis. Incidence rates for all periods peak at the 45- 50 age group and 
again at the 75- 80 year age group (Figure 2.4a). Rates by age vary little by period except for the 
25-29 year age group that shows an increase in incidence rates from 2000-2004 and the 85+ age 
group that increases sharply from 1995 to 2009. As expected, older age groups and birth cohorts 
have greater incidence rates as compared to younger subjects (Figure 2.4b, 2.4c, 2.4d). For a 
given age, there seems to be an increasing trend by birth year (Figure 2.4d). 
Model fits. AC-P and AP-C models were fit for all females and females grouped by age 
(<50 and 50+). The Akaike Information Criteria for each model is shown in Table 2.2 27. The 
AC-P model for all females shows an age effect that increases with age (Figure 2.5a, left). The 
crude rate, which corresponds to the birth-cohort of 1948, increases sharply from age 32 to 52, 
going from 6.0 to 59.7 cases per 100,000. From age 57, the crude rate climbs from 76.4 to its 
peak at 140.3 cases per 100,000 person-years at age 82. In terms of cohort effects, the first 
cohort, 1902, has a 0.12 times lower risk of breast cancer as compared to those born in 1948 
(Figure 2.5a, center). Conversely, those born in 1976 have a risk about two times higher 
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compared to those born in 1948. Cohorts after this year have low observations and large 
confidence intervals and therefore their higher relative risks must be interpreted with caution. 
Estimated period effects for this model are close to the relative risk of 1 (Figure 2.5a, right).   
The AP-C model for all females shows an age effect that increases sharply until age 57 
where it peaks with a crude incidence rate corresponding to the year 1992, of 42.5 cases per 
100,000 person-years (Figure 2.5a, left). This trend decreases down to 28.4 cases per 100,000 for 
age 67, but then peaks again at 30.1 cases per 100,000 for at age 77. The period effect remains 
close to the reference level until 1998 when the risk for breast cancer increases and continues to 
increase up to 1.9 times greater than the reference in 2010 (Figure 2.5a, right). The cohort effect 
for the AP-C model remains close to 1 (Figure 2.5a, center). 
The estimated age-period and cohort effects for the models by age (<50 and 50+) are consistent 
with those from the all female model (Figure 2.5b and 2.5c). 
  
Projections  
We used a variety of approaches to assess the validity of the projection of breast cancer 
rates in Songkhla through variability across model predictions28. We first used the joinpoint 
models to project incidence trends to 2029 for all females and for females grouped by age 
(Figure 2.6). Observed data from 2000-2010 was used as the basis for all projections to avoid 
influence from the notable drop in rates from 1995-2000. Projections based on all years (1990-
2010) were also made for comparison and are shown in Figure 2.7. We found that incidence rates 
are expected to continue to increase to 29.2 cases per 100,000 person-years or 241 cases per 
year, in 2029. Females below the age of 50 are expected to reach 12.0 cases per 100,000 person-
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years in 2029 (62 cases) while females at or above age 50 are predicted to reach 103.8 cases per 
100,000 person-years, or 323 cases per year, in 2029 (Figure 2.6a, 2.6b).  
The second approach used Nordpred to project trends up to the year 2029. Incidence rates 
for all females are expected to reach 30.7 cases per 100,000 person-years, or 252 cases per year, 
for period 2025-2029. For females below age 50, rates are expected to rise to 13.7 cases per 
100,000 person-years, or 72 cases per year, while females at or above age 50 are expected to 
have an incidence rate of 91.3 cases per 100,000 person-years, or 273 cases per year, for the 
period 2025-2029 (Figure 2.6c, 2.6d).  
The third approach projected rates using the AP-C and AC-P models. For the AC-P 
model, data was used for the cohorts from 1902 to 1972. While the estimated incidence rates did 
not differ greatly in a sensitivity analysis (shown in Figure 2.7), using this approach with 
censored observed data was deemed more appropriate due to small sample sizes in later cohorts. 
Incidence rates for all females reach 38.9 cases per 100,000 person-years (321 cases), 17.7 cases 
per 100,000 person-years (91 cases) for women under age 50, and 107.0 cases per 100,000 
person-years (333 cases) for women at or above age 50 in year 2029 (Figure 2.6e, 2.6f). 
According to the projected AP-C model, incidence rates for all females are expected to 
continue to increase to 51.4 cases per 100,000 person-years, or 424 cases per year, in 2029. 
Females below the age of 50 are expected to reach 28.3 cases per 100,000 person-years, or 146 
cases in 2029, while females at or above 50 incidence rates are projected reach 195.6 cases per 
100,000 person-years, or 609 cases, in 2029. 
 For comparison purposes, we have repeated the joinpoint and AC-P projections using all 
available data as the basis for prediction and repeated the Nordpred analysis using data from only 
the last ten years to project incidence rates and cases into the future. The joinpoint projections 
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increase slightly for all females and for the age groups. Our original analysis forecasted rates to 
be 29.2, 12.0 and 103.8 cases per 100,000 for all females, females below age 50 and females at 
or above age 50, respectively, in 2029. This translates to 241, 62 and 323 cases per year, 
respectively. Including all the observed data, these incidence rates decreased slightly to 28.7, 
14.0 and 105.6 cases per 100,000 for all females, females below age 50 and females at or above 
age 50, translating to 238, 72, and 328 cases per year, respectively (Figure 2.7a, 2.7b). Although 
the results do not change much through inclusion of all data, our limitation of observed data to 
base projections off of is appropriate due to the uncharacteristic drop in incidence rates from 
1995-2000. This is likely due to improper identification of cancer cases.   
 Using observed data for the last 10 years to project future rates is a common method in 
Nordpred analysis due to the rational that recent trends in incidence rates are more likely to be an 
influence in future rates. Using the recent trend as a basis for future predictions incidence rates 
are projected to decrease to 24.3 cases per 100,000 person-years for all females for the period 
2025-2029, or 200 cases per year (Figure 2.7c, 2.7d). Although this was included for comparison 
purposes, the use of historical trend for projections is a more accurate depiction of future 
projections since there nothing significant was introduced, such as screening, which would 
impact future incidence rates of female breast cancer. 
Cohorts by which to base projections on for the AC-P model began in 1902 and were 
limited to 1972 due to the small number of cases (≤10) from cohorts after 1972. To compare 
results, the projection was repeated using all available cohorts with cases (1902-1988).  This 
approach changed the projected incidence rate for all females from 38.9 to 46.0 cases per 
100,000 person-years, or 321 to 380 cases in 2029. The incidence rate for females below age 50 
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changed from 17.7 to 28.7 cases per 100,000 person-years, or 91 to 148 cases in 2029. Results 
for the women at or above age 50 did not change (Figure 2.7e, 2.7f). 
 
DISCUSSION 
This study showed that breast cancer incidence in southern Thailand has increased 
significantly since 1990, likely due to a combination of changes in demographics and the risk 
profile of the population, as well as increases in surveillance and breast cancer awareness. 
Projections from various models consistently show that the burden of breast cancer in Southern 
Thailand will continue to rise in the near future, potentially reaching a rate of about 29-51 cases 
per 100,000 PY for all females in 2029, although the magnitude of the increase could 
hypothetically be affected by future healthcare planning and other cancer burden control 
measures. 
These data highlight the utility of surveillance data in LMICs with increasing rates of 
cancer.  A strength of this study is the carefully collected data in Songkhla province. The Thai 
NCI has put considerable resources into training surveillance staff through standardization of 
ICD-O coding protocols, data reporting, collection and entry. Thus these are high quality data to 
construct robust and informative models. However, the registry data are limited due to the lack 
of information on biomarkers, religion, and other lifestyle characteristics. To date, there has not 
been comprehensive collection of this information at the population-level. Our research group is 
actively developing protocols to collect population-based data to identify novel risk factors for 
breast cancer in this population, to augment the utility of the existing registry data.  
Generally, incidence rates for all females and for both age groups above and below the 
mean age at menopause (<50 years and ≥50 years) show increases in breast cancer incidence 
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from 1990-2010. As expected, the older age group has a higher incidence rate, contributing 
significantly to the overall trend for all females. The only significant increase in incidence for 
females under age 50 was during 1990-1995. Younger women in southern Thailand tend to be 
more aware of early detection measures, such as breast self-examinations, which could explain 
this significant increase. However, risk profiles for younger women tend to be low which may 
explain why the overall APC remained lower than that for all females and females at or above 
age 50.  However, a limitation of this study is that we do not have case ascertainment 
information since the start of the registry. It has likely changed over time and may contribute 
somewhat to the increase in incidence rates over time. Nonetheless, we expect the impact to be 
limited since the registry follows very strict protocols for case identification.  
It is difficult to ascertain if female breast cancer trends for southern Thai women are 
influenced predominantly by period or cohort effects. From Figure 5, we can see that both the 
AC-P model and the AP-C model fit the data well as the third parameter in each model hovers 
around the relative risk of 1. Age-specific rates in Figure 4 do not show proportionality between 
periods or cohorts, indicating the incidence trend is not shaped by either effect alone. Rather, the 
analysis shows that both period and cohort effects are both relevant in shaping the trends and so 
we chose to present both models and to make projections with each. Similar results have been 
shown in other populations29, 30. However, consistent with reports from other countries 31, there 
are indications of a stronger cohort effect. The AIC of the AC model is lower than that of the AP 
model, demonstrating a better fit for this model to the data (Table 2).  The age effect estimates of 
the AC-P model exhibit the well-known ‘Clemmensen’s hook’ where incidence rates increase 
exponentially until around age 50, and dip slightly before rising again at a lower rate. This 
phenomenon has been observed for breast cancer incidence and mortality across countries and is 
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thought to be due to the overlap of rates between pre- and post-menopausal women32, 33.  The 
projections with the AC-P model are also more consistent with the two other methods than those 
from the AP-C model.  
The ASR for all women in southern Thailand increased from 10.0 in 1990 to 27.8 cases 
per 100,000 person-years in 2010. Compared to a high income country, such as the United States 
where the ASR in 2010 was 126 cases per 100,000 person-years, this incidence is still relatively 
low, although this is likely a consequence of the lack of population-level breast cancer screening 
throughout Thailand34. In comparison to other LMICs, Thailand does still fall on the lower end 
of breast cancer rates. The ASRs from 1998-2002 in Korea, Taiwan, Hong Kong and Singapore 
were 37.2, 59.7, 69.1 and 90.1 cases per 100,000 person-years, respectively35.  However, 
Thailand is undergoing an epidemiologic transition in lifespan and lifestyle characteristics 
combined with a shift from infectious to chronic diseases. For example, the average life 
expectancy in Thailand for females is expected to increase from 77.5 years in 2010 to 80.1 years 
in 202014. Concordantly, the percentage of southern Thai women aged 50 and over increased 
from 15.3% in 1990 to 18.1% and then to 23.0% in 2000 and 2010 15-17.  Our registry data show 
that the risk of breast cancer is highest for this age group and our projections suggest that it will 
continue to increase at a higher rate compared to women below 50. There is also considerable 
evidence that southern Thai women are adopting a Western lifestyle. The percentage of southern 
Thai women who are overweight (BMI ≥ 25 kg/m2) increased from 36.3% in 2004 to 40.7% in 
2009. The average percentage of southern Thai women with diabetes increased from 5.06% in 
2004 to 6.0% in 2009. Hypertension in southern Thai women increased from 20.9% in 2004 to 
21.4% in 200936. Considering parity, the total fertility rate in Thai population has been gradually 
decreasing from 6 in 1970 to 3 in 1985, 2 in 1998 and 1.6 in 201037.   
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This shift in risk profiles of southern Thai women makes it necessary to focus on early 
detection and awareness of breast cancer. Young women especially are aware of the importance 
of screening. Within the past year, 66.9% and 12.3% of southern Thai women aged 15-59 years 
have conducted self breast examinations and clinical examinations, respectively, while the 
national adherence for these techniques is 60.7% and 17.9%36.  The rates of breast self-
examination in Thailand are higher in comparison with other LMICs such as Malaysia (46.8%) 
as well as with more developed countries such as Greece (21.4%) and the United Kingdom 
(24.8%) 38, 39. In contrast, clinical examination rates are low with respect to other countries36. 
Mammography is not an established early detection measure in southern Thailand due to a 
general lack of trained radiologists to read mammographies and that this diagnostic tool is not 
covered by Thai universal health care. Therefore, it is crucial to identify population factors in 
breast cancer trends in Thailand to create targeted prevention strategies.  
To assess the future breast cancer burden in Southern Thailand, we projected out the 
observed trends to the year 2029 using a variety of methods. All approaches have advantages and 
limitations; therefore, we decided to include them all with the intention of drawing conclusions 
based upon commonalities from various methods.  There is a clear agreement from all our 
models that female breast cancer incidence rates will continue to increase. Predictions made with 
the aggregated 5-year periods using nordpred were similar to joinpoint predictions made with 1 
year periods. Projected rates were 29.2 to 30.7 cases per 100,000 person-years, 12.0 to 13.7 cases 
per 100,000 person-years and 91.3 to 103.8 cases per 100,000 person-years for all females, 
females less than 50 and females at or above 50, respectively, in 2029. For purposes of 
understanding future breast cancer incidence trends, the projections these models are thought to 
be a lower bound of future rates.  
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The APC models used 1-year periods and projected 38.9 to 51.4 cases per 100,000 
person-years for all females, 17.6 to 28.3 cases per 100,000 person-years for females under 50, 
and 107.0 to 195.6 cases per 100,000 person-years at or above 50. These ranges are wide; 
however they give an indication of the potential magnitude of breast cancer incidence rates in the 
future. With the current lack of early detection measures, such as mammography, we can expect 
that future incidence rates of breast cancer will increase only towards the lower limits of the 
projections and likely be late-stage and have poor survival rates. However, if early detection 
measures were introduced into universal health care coverage, future rates may increase to the 
upper end of these projections, but present at earlier stages and increase the probability of 
responding to treatment. Specifically, the increase in the proportion of women 50 and above in 
the population combined with their elevated risk for breast cancer as shown in this paper, 
identifies this group for targeted intervention.   
 
CONCLUSIONS 
This study provides the first in-depth look at the epidemiology of breast cancer in 
southern Thailand. Because of the changing risk profile of the women in this region, these 
findings need to be extended to characterize the population in terms of diet, lifestyle, and genetic 
factors. Future research should be directed towards strategies to control the burden of breast 
cancer in Thailand.   
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Table 2.1: Joinpoint trends in female breast cancer incidence rates in Songkhla, Thailand 
  
Trend 1 Trend 2 Trend 3 Trend 4 
Age N Years APC 
 
Years APC 
 
Years APC 
 
Years APC 
All 2545 1990-1997 1.55 
 
1998-2000 15.08 
 
2001-2010 1.90* 
   
<50 1280 1990-1995 10.73* 
 
1996-1998 -7.92 
 
1999-2000 30.83 
 
2001-2010 0.1 
>50 1265 1990-2010 4.63* 
         
Abbreviation: APC Annual Percentage Change                                                                                                                                                                                                                                                     
*APC is significantly different from zero p<0.05  
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Table 2.2: Akaike information criteria (AIC) values for the AC, AC and APC models 
relative (difference) to the Age only model** 
 
Model 
 
AIC* 
 
 
Age-Period 
 
-161.68 
 
 
Age-Cohort 
 
-163.63 
 
 
Age-Period-Cohort 
 
-184.93 
 *'-2 x log(likelihood) + 2 x number of estimated parameters. 
**Relative values that weight the goodness of fit of the model to empirical data. The lower the AIC, the better the model fit. 
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Figure 2.1: Map of Thailand. Songkhla province is highlighted 
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Figure 2.2: Stage distribution across five-year periods for women below age 50 (2a) and women at or 
above age 50 (2b). Age-adjusted standardized rates by stage for each year for women below age 50 (2c) 
and women at or above age 50 (2d). The percentage of local cases showed the largest increase in women 
below the age of 50 (2a) from 2000-2009, while the percentage of regional cases increased steadily over 
the time period. Both local and regional cases increased steadily for women at or above age 50 (2b). 
Percentage of distant and unknown cases decreased steadily for both age groups. Age-adjusted rates for 
both age groups show an increase in incidence of local cancers and a notable increase for regional 
cancers, while incidence rates of unknown cancers decrease (2c, 2d). NOTE: Y-axis have different ranges 
between 2c and 2d. 
 
 
 
40	  
	  
Figure 2.3: Trend analysis of age-adjusted breast cancer incidence trends for females from 1990-2010. 
Trend analysis of age-adjusted breast cancer incidence trends for females from 1990-2010. (*) denotes an 
APC significantly different from zero. a) Age-adjusted incidence trends for all females b) Age-adjusted 
incidence trends for females under 50 years of age c) Age-adjusted incidence rates for females age 50 
years and older d) Comparison of age-adjusted incidence trends for females below and at or above age. 
NOTE: Y-axis have different ranges. 
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Figure 2.4: Incidence of female breast cancer in women per 100,000 person-years by age, period and 
birth cohort. Incidence rates by period (a), birth cohort (b), and age (c,d). 
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Figure 2.5: APC trend analysis. AC-P (blue) and AP-C (red) models for a) all females, b) females under 
the age of 50 and c) females at or above the age of 50. Incidence rates are plotted in the log scale (left y-
axis). 
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Figure 2.6: Breast Cancer incidence trend projections to 2029. a) Rate projections for all females and by 
age group using the joinpoint model b) Case projection for all females from the joinpoint model c) Rate 
projections using nordpred d) Case projections for all females using the projection from the nordpred 
model e) Rate projections from the AP models f) Case projections for all females from the APC models 
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Figure 2.7:  Rate and case projections for models included for comparison purposes. a) Rate projections 
for all females and by age group using the joinpoint model with all observed data included b) Case 
projection for all females from the joinpoint model with all observed data included c) Rate projections 
using the Nordpred model, but only including the last 10 years for the observed data d) Case projections 
for all females using the projection from the Nordpred model using only the recent trend from the last 10 
years e) Rate projections from the APC models (AP-C and AC-P). The AC-P model used all available 
cohort information to base predictions off of f) Case projections for all females from the APC models in 
e). 
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CHAPTER 3 
Biomarkers of effect from Cd exposure that may indicate early adverse 
health outcomes including carcinogenesis 
 
ABSTRACT 
Background:  Cadmium (Cd) is a known human carcinogen, however, much of what is known 
about the biological effects of cadmium (Cd) comes from in vitro and animal studies. Evidence 
from these models has linked Cd to epigenetic changes, although there is limited evidence in 
human populations.  
Objectives: The objective of this study is to determine the association between DNA methylation 
markers and renal biomarkers with Cd exposure, taking into account sex differences, to identify 
potential biomarkers of effect resulting from Cd exposure that may lead to carcinogenesis.  
Methods: One hundred and sixty-nine residents from known exposure areas of Mae Sot, Thailand 
and one hundred residents from non-exposed areas nearby were surveyed in 2012. Demographic 
information and urine/blood samples were collected for measurement of urinary Cd (UCd), 
methylation of Cd-related markers (DNMT3, MGMT, LINE-1, MT2A) and renal marker levels 
(NAG, serum creatinine).  
Results: UCd levels were about 7 times higher in the exposed compared to the non-exposed 
population (unexposed median: 1.04 µg/L, exposed median: 7.41 µg/L, p <0.001). MGMT 
methylation was significantly lower in the exposed population. UCd was significantly associated
with all renal biomarkers. Sex differences were seen in exposure groups for DNMT, LINE-1 and 
MGMT methylation. Several markers were associated with both UCd and renal markers by 
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gender including MT2A and DNMT in females and LINE-1 and DNMT in males. Mediation 
analysis revealed LINE-1 methylation slightly mediated the effect of urinary Cd on B2MG in 
males. 
Conclusions: Environmental Cd exposure induces DNA methylation changes that are dependent 
upon sex. DNA methylation changes are associated with altered levels of renal biomarkers, 
which may precede Cd-induced carcinogenesis 
 
Abbreviations: Cd (cadmium), UCd (urinary cadmium), β2MG (beta 2-microglobulin), NAG (N-
acetyl-beta-D-glucosaminidase), UCr (urinary creatinine), SCr (serum creatinine) 
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INTRODUCTION 
 Cadmium (Cd) is a biologically toxic transition metal found in low levels in 
nature and high levels from anthropogenic sources1, 2. Non-occupational exposures occur from 
tobacco smoke and ingestion of contaminated food and water and are associated with kidney 
damage including chronic renal diseases, osteoporosis, cardiovascular diseases, multiple cancers 
and osteomalacia1-4  both in the US5-7  and globally8-10. Cd is known to sequester in the liver and 
kidney and replace calcium in the bone11, 12.  Occupational exposures first linked acute Cd 
exposure to lung, nasal, breast, kidney and pancreatic cancers13-17  and the International Agency 
for Research on Cancer (IARC) has classified cadmium as a Group 1 human carcinogen3, 4.  
However, less is known about the carcinogenicity of Cd at low-to-moderate levels of exposure. 
The US Third National Health and Nutrition Examination Survey (NHANES) revealed an 
association of urinary Cd with cancer mortality over a 13-year follow-up period18. The 
associations found in men were for urinary Cd and mortality from lung and pancreas and with 
non-Hodgkin lymphoma cancers whereas for women the association was found for leukemia, 
lung, ovaries, and uterine cancers18. Cd exposure has been associated with breast and 
endometrial cancers in other populations as well5, 19-21.  
Although the association between UCd and cancer incidence/mortality is well-described, 
the mechanism by which Cd exerts its biologic effects is unclear. Although there is a lack of 
mechanistic studies in humans, in vitro and animal studies have provided evidence linking Cd to 
carcinogenesis (Table 3.1)5, 22-25. Cd weakly binds to DNA, is indirectly genotoxic and poorly 
mutagenic, indicating that it does not initiate disease through direct interaction with DNA26, 27. 
Cd is known to cause aberrant expression of a variety of genes including the oncogenes c-myc 
and c-jun28, translation elongation factor-1 and 329, and AP-1 and MAP kinases, which are 
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involved in signaling pathways30. Specifically, Cd has been shown to affect DNA methylation, 
although the direction of effect is unclear. Many studies have implicated these epigenetic 
changes in the process of tumorigenesis28-30 23. Inactivation of tumor suppressor genes p16 and 
RASSF1A in Cd-transformed malignant human prostate cells was found to be due to silencing of 
promoter regions from hypermethylation and correlated with DNMT3B overexpression23. 
Similarly, increased DNA methylation and DNMT activity were seen in human embryo 
fibroblasts after two months of Cd exposure31 . However, Huang et al. found that DNA was 
hypomethylated in a leukemia K562 cell line only 24 and 48 hours after Cd exposure32.  Cd 
exposure to normal human breast epithelial cell line MCF-10A for 40 weeks resulted in 
transformation of cells to basal-like breast carcinoma cells, with DNA hypomethylation and 
overexpression of c-myc and KRAS, as is commonly seen in aggressive breast cancers22. Cd was 
found to induce hypermethylation of caspase-8 in the liver of mice and RASAL1 and KLOTHO in 
a Chinese population exposed to low levels in the environment33, 34.  This evidence from 
previous studies suggests that changes in DNA methylation occur in response to Cd exposure. 
It is difficult to assess initial molecular events in response to Cd exposure in cancer 
patients because cancer takes a long time to develop and there are likely numerous biological 
pathways that become dysregulated to initiate a cancerous phenotype. However, the low-dose 
exposure levels that have been associated with various cancers overlap with those shown to 
induce adverse kidney and bone defects (Table 3.2; Table 3.3). This offers an intermediate 
outcome with which to associate initial molecular events in response to Cd exposure that may 
fall along the pathway to cancer. 
Renal dysfunction is well characterized in response to Cd exposure and is diagnosed with 
discrete clinical parameters measuring levels of specific renal biomarkers. Candidate gene 
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studies have identified DNA methylation markers associated specifically with Cd-induced 
kidney damage. Increased DNA methylation and DNMT activity were seen in human embryo 
fibroblasts after two months of Cd exposure31. Hypermethylation of tumor suppressor RASAL1 
and renal fibrosis inhibitor KLOTHO, was found to be strongly associated with both blood and 
urinary Cd levels and with renal fibrogenesis34-36. Additionally, Cd-induced gene-specific DNA 
hypermethylation has been reported for genes involved in cell cycle regulation, DNA repair, 
apoptosis and cell proliferation33, 37-39. Hypermethylation can prevent transcription of these 
important genes and promote initiation of disease. These studies show that Cd induces epigenetic 
alterations, which may fall along the molecular pathway of Cd exposure and renal dysfunction, 
and eventually, cancer.  
Mae Sot District in the Tak Province of Thailand is located on the country’s northwest 
border and is an area of high cadmium contamination due to a long standing zinc mine (Figure 
3.1). Several subdistricts have been determined to have Cd levels in soil and rice exceeding Thai 
standards of 0.15mg/kg of soil and 0.043mg/kg of rice40. These standards reflect levels at which 
human exposure may result in adverse health effects41. A study conducted in Mae Sot in 2004 
found a subset of residents that had urinary Cd (UCd) levels ≥5ug/g creatinine to also have 
irreversible renal dysfunction, indicated by clinical parameters of renal marker levels12, 42.  UCd 
levels above this have been shown to induce preclinical renal dysfunction and have been deemed 
as a human exposure standard by the WHO43. However, a separate study found significant 
changes in renal biomarkers at much lower exposures, below UCd levels of 0.5ug/g creatinine, 
leading to concern about the effects of chronic, low-level exposures to Cd44.  Sex differences in 
body burden and health outcomes in response to Cd exposure have been widely reported45-47. 
However, epigenetic changes in response to Cd exposure have not been considered within this 
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context, mostly because much of what we know about Cd induced epigenetic changes come from 
animal model or in vitro studies. Additionally, epigenetic changes associated with biomarkers of 
Cd-induced renal dysfunction are currently unknown. The objective of this study is to determine 
the sex-specific associations between UCd and methylation of selected genes and between these 
genes and renal biomarkers to clarify the role methylation may play initially in the pathway from 
Cd exposure to adverse renal outcomes and eventually, to cancer. These genes include MT2A 
(metallothionein 2A), DNMT3 (DNA methyltransferase) and MGMT (DNA repair protein), all of 
which have been found to be altered in the presence of cadmium in animal model and in vitro 
studies23, 39, 48, 49 . Additionally, methylation of LINE-1, a retrotransposon, was determined as a 
measure of genomic stability22 . Renal biomarkers including NAG (N-acetyl-beta-D-
glucosaminidase), and SCr (serum creatinine), were chosen based on their use as clinical 
indicators of renal dysfunction.  Because Cd exerts different biological effects based upon sex, 
we hypothesize that methylation markers are associated with both UCd and renal biomarkers and 
differ by sex. 
  
METHODS 
Study Population 
One hundred and sixty-nine subjects were selected from Mae Ku, Mae Tao and Phra Thad 
Padang subdistricts, areas in the Mae Sot District known to be contaminated with Cd due to their 
proximity to the Mae Tao creek50. These subjects were selected from a larger sample of 700 
subjects who participated in a health impact survey conducted in 200751, 52. The subjects in the 
Cd polluted area were at least 40 years old and were selected based on levels of β2-MG and Cd in 
urine collected in 2007. The exposed population consisted of 47 men and 37 women with marked 
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renal tubular dysfunction (β2-MG ≥ 1000 µg/g Cr) and high UCd (UCd ≥ 5 µg/g Cr), and 36 men 
and 48 women with no clear renal dysfunction (β2-MG < 300 µg/g Cr) and low UCd exposure 
(UCd < 5 µg/g Cr).   One hundred subjects aged 40 years and above were chosen from the Mae 
Kasa subdistrict, a non-contaminated area of Mae Sot. Trained health workers interviewed each 
participant about demographic characteristics, occupation, residency time, smoking status, and 
alcohol consumption. Medical history of hypertension, diabetes, and urinary stones was obtained 
from medical records at Mae Sot General Hospital. The research ethical committee of the 
Faculty of Medicine, Chiang Mai University, approved this study. (Approval No. 004/2012) 
 
Sample Collection and Processing 
Twenty-five mL of morning urine were collected from each participant in Cd-free polyethylene 
containers. Urine was immediately tested qualitatively for pH and chemical specific gravity (SG) 
using paper indicator strips (Ames test, Siemens, Germany) on site. One drop of 0.5N sodium 
hydroxide was added to one of the aliquots if it had a pH of ≤5 for prevention of further 
degradation of β2MG in an acid condition.  
Ten milliliters of fasting venous blood was obtained by cubital venipuncture, and then divided 
into two Cd-free polyethylene tubes with and without EDTA.  All samples were transported on 
ice to Mae Sot General Hospital’s Laboratory within two hours of collection. Whole blood with 
EDTA and urine samples were stored at -20°C until analysis. Creatinine in sera obtained from 
blood in tubes without EDTA was determined by the Jaffe reaction method using an automated 
analyzer (Konelab 30, Thermo Electron Corporation, Finland) in Mae Sot hospital. White blood 
cell counts were measured using an automated hematology analyzer (HmX Hematology 
Analyzer, Beckman Coulter, USA). Frozen urine samples were transported with dry ice to 
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Kanazawa Medical University, Japan for urinary biomarker measurements. The concentration of 
urinary β2MG was measured via enzyme immunoassay using a latex agglutination immunoassay 
(Eiken Chemical, Japan); urinary NAG was measured via a colorimetric assay using the NAG 
test kit (Shionogi Pharmaceuticals, Japan); urinary creatinine (Cr) was measured via an enzyme 
assay using the Cica liquid-Stest kit (Kantokagaku Reagent Division, Ltd., Japan).  Frozen whole 
blood with EDTA and urine samples were transported on dry ice to the University of Michigan 
for DNA collection and cadmium measurements. 
 
Urinary Cadmium Measurement 
Specific gravity of each sample was determined with a refractometer (PAL-10S, Atago Inc., 
USA). Urinary Cd was measured at the Michigan Department of Community Health.  Briefly, 
urine samples were diluted 1:10 with a diluent composed of 2.0% nitric acid, internal standards 
and 0.05% Triton X, and Cd concentrations were determined using ICP-MS (DRCII , 
PerkinElmer, USA).  The analytical accuracy using QMEQAS08U urinary standard reference 
material (Institut national de santé publique du Québec, INSPQ) was 101.1% (n=8) and all 
samples were above the analytical detection limit of 0.15 ug/L. 
 
DNA Sample Preparation  
DNA was extracted from 300uL of whole blood using the QiaAMP DNA Mini Kit (Qiagen, 
Valencia, CA, USA). DNA concentration and purity was quantified using the Nanodrop 
(ThermoScientific, Wayne, MI, USA) and DNA stored at -20C until methylation analyses. 
Sodium bisulfite modification was performed on 500ng of genomic DNA using the Epitect 
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Bisulfite Kit ((Qiagen, Valencia, CA, USA) according to the manufacturer’s recommended 
protocol.  
 
DNA Methylation Measurements 
Methylation assays for 3 genes - MT2A, DNMT3 and MGMT, were designed using PyroMark 
Assay Design 2.0 software. LINE-1 was measured using a previously published assay53.  
Bisulfite singleplex PCR amplification was performed using FastStart Taq Polymerase (Roche 
Diagnostics, Indiana, USA) with a forward and reverse primer concentration of 0.2 mM and 
10ng/uL of bisulfite-converted DNA. Fifteen microliters of each PCR product was combined 
with the respective sequencing primer and methylation analysis by pyrosequencing was 
conducted for each assay as previously described54. Complete coverage of all samples for every 
methylation marker selected was not possible due to low quantity of total extracted DNA. 
 
Statistical Analysis 
Correlation between Cr-adjusted, SG-adjusted and unadjusted values was calculated using the 
Spearman method. All renal biomarkers and urinary cadmium levels were adjusted by specific 
gravity (SG) to adjust for all dilution-related variation of U-Cd55. Urinary markers were 
standardized to the median specific gravity of the control population with the following formula: 
Bc = B[(1.017 - 1)/SG - 1)], where Bc  is the SG-corrected urinary biomarker, B is the observed 
biomarker level, 1.017 is the median SG of the unexposed population, and SG is the specific 
gravity of the individual’s urine sample 56. Nonparametric Kruskal-Wallis tests were used to 
compare total exposed and unexposed populations and exposure populations by sex.  Findings 
were determined to be statistically significant at p-value<0.05.   
54	  
	  
Linear regression models were performed to determine the associations of urinary cadmium with 
each methylation marker. Each marker was also tested as a predictor of each renal marker.  
Methylation changes were standardized to an interquartile range (IQR) increase in UCd levels. 
Methylation units were in 1% increments. Due to departures from normality, UCd, all 
methylation markers and all renal marker values were log-transformed for regression analysis 
and models were interpreted as percent increases in predictor associated with percent changes in 
outcome. Because age is associated with cadmium and renal marker levels, all models were 
adjusted by age. Sex is associated with cadmium and affects levels of renal markers; therefore, 
these models were stratified by sex.  
 
Model Selection for Multivariable Models 
To determine covariates to be included in final versions for each renal model, best-fit models 
were chosen separately for the exposed and unexposed population. A stepwise algorithm was 
first used to determine a multivariable model for each renal marker in each group, adding in 
variables in both backward and forward modes based on Akaike information criterion (AIC). 
Covariates in the full model included: urinary Cd, age, occupation, smoking status, gender, white 
blood cell count, hgb, BMI, alcohol use, and history of diabetes, hypertension and urinary stones. 
Variables included as predictors in each model by exposure group were then combined into one 
final model for each renal marker and run with the entire study population to accurately assess 
relevant predictors of renal marker levels. A priori predictors such as age and medical history 
were not significant in all models and were therefore, reintroduced into the final models since 
they are known to be associated with cadmium exposure and methylation. Final models were 
stratified by gender.  
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Causal Mediation Analysis 
To test whether methylation markers may mediate the effects of urinary cadmium on renal 
biomarkers, a mediation analysis was conducted in four steps. Methylation markers were tested 
individually as each marker represents a separate potential mechanism of Cd toxicity. First, the 
association between urinary Cd and each renal biomarker was tested for significance (α=0.05) in 
a regression equation. Second, the association between urinary Cd and each methylation marker 
was tested for significance in a regression equation. Third, the association between each 
methylation marker and each renal marker was tested for significance with urinary Cd in the 
model. Any methylation marker that did not reach significance at the α=0.05 level was not 
considered as a mediator. Upon determination of potential mediators, methylation markers were 
tested for mediation effects using the final best-fit multivariable models. Using the mediation 
package in R, the average causal mediation effect (ACME), average direct effect (ADE) and the 
total effect was first calculated in the multivariable model without the methylation marker to 
determine the effect UCd had on the renal biomarker alone. Then, the methylation marker that 
was found to be a potential mediator was added to the model to determine its mediation effect 
(Figure 3.2). Significance of the mediation effect was measured by comparison to the sampling 
distribution created using the bootstrap method, a non-parametric method that uses resampling 
with replacement (n=2000) to create a sampling distribution of indirect effects.  
R-statistical software was used for all analyses (R version 3.0.1) 
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RESULTS 
Correlation among UCd measurements with different correction methods 
 Correlation of various correction methods was measured over the total population. 
Correlation coefficients for unadjusted UCd and SG-adjusted UCd and for SG-adjusted and Cr-
adjusted UCd were similar (rho=0.95, p<0.0001). The correlation coefficient for unadjusted UCd 
and Cr-adjusted UCd was slightly lower (rho=0.87, p<0.0001). 
 
Comparison of all markers between exposed and non-exposed groups 
 Median levels of UCd were nearly seven times higher in the exposed population 
than the unexposed population (p <0.001) (Table 3.4). The ranges of exposure between 
populations slightly overlap, however the exposed population has a much wider range with 
higher exposure levels than the unexposed population. There were significant differences in 
urinary markers by exposure group including UCd, specific gravity, β2MG, NAG, and Scr. 
Subjects in the Cd exposed population had significantly lower levels of SG than those in the 
exposed population. Levels of β2MG, NAG and SCr were all significantly higher, while MGMT 
methylation was significantly lower in the Cd exposed population as compared to the unexposed 
population.  
 Demographically, the proportion of regular smokers was highest in the Cd exposed 
population, of which 66% were male, whereas the unexposed population had similar proportions 
of never, former and regular smokers (Table 3.5). Half of the Cd exposed population had 
hypertension (HT) compared to forty percent of the unexposed population. The majority of the 
unexposed population was farmers (74%) compared to only fifty percent in the Cd exposed 
population.  
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Comparison of all markers by sex 
 Within the unexposed area, women had significantly higher levels of UCd as 
compared to men. In these women, levels of β2MG were significantly higher; however, levels of 
Scr, UCr and DNMT methylation were significantly lower than unexposed men (Table 3.6). In 
contrast, Cd-exposed women had significantly lower levels of UCd compared to Cd-exposed 
men, as well as lower levels of NAG, SCr, and LINE-1 methylation.  
 Exposed men had significantly higher levels of UCd, β2MG, NAG, SCr, and 
DNMT methylation, but lower MGMT methylation levels compared to unexposed men. Similar 
trends were seen in women across exposure group. Exposed women showed significantly higher 
levels of UCd, β2MG, NAG and SCr, but lower levels of MGMT methylation, compared to 
unexposed women (Table 3.6).   
 
Associations between UCd and methylation markers 
 Regression analyses adjusted for age showed distinct associations of methylation 
markers to UCd (Figure 3.3). For the total population, MGMT methylation decreased by 16.6% 
with an interquartile (IQR) increase in UCd levels (p<0.001). In men, a 24.7% decrease in 
MGMT methylation was significantly associated with an IQR increase in UCd (p =0.003). There 
was also a significant increase in men of about 1% in LINE-1 methylation with an IQR increase 
in UCd (p =0.04). In women, DNMT methylation decreased by 8.5% and MT2A methylation 
decreased by 7.4% with an IQR increase in UCd (p =0.05, p =0.03, respectively). Methylation 
markers were not correlated with each other.    
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Associations between methylation markers and renal biomarkers 
 Renal biomarkers were significantly associated with UCd and several methylation 
markers (Table 3.7). All changes in renal biomarkers reflected a 1% increase in methylation. In 
the total population and populations separated by sex, all renal biomarkers were positively 
associated with an IQR increase in UCd. In the total population, a 1% increase in LINE-1 
methylation was associated with a 15.1% increase in β2MG (p =0.01) while an increase in 
MGMT methylation was associated with a 0.8% decrease in β2MG (p =0.02). In males, LINE-1 
methylation was associated with a 32.7% increase in β2MG (p <0.001), MT2A methylation was 
associated with a 1.4% increase in β2MG (p =0.01), while MGMT methylation was associated 
with a 0.9% decrease in β2MG (p =0.04). In females, a 1% increase in DNMT methylation was 
associated with a 1.5% decrease in β2MG (p =0.04).  
 LINE-1 methylation was associated with a 4% increase in NAG in the total 
population (p =0.01). In males, NAG increased by 5% and 0.3% with a 1% increase in LINE-1 
and MT2A methylation, respectively (p =0.04; p =0.04, respectively). In females, MT2A 
methylation was associated with a 0.7% decrease in NAG (p=0.007).  
 In the total population, LINE-1 and MGMT methylation were associated with a 
1.2% increase and 0.1% decrease in SCr, respectively (p =0.03; p =0.03). In males, LINE-1 
methylation was associated with a 2.5% increase in SCr (p =0.001), while in females, MGMT 
methylation was associated with a 0.1% decrease in SCr (p =0.04).   
 
Predictors of Renal Markers  
 Out of the final models for the unexposed population, UCd was fit as a predictor 
only for NAG. In the exposed population, UCd was a significant predictor for all renal markers 
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(Table 3.8).  Predictors from exposed and unexposed models were combined for each renal 
marker (Table 3.9) These final three models were then stratified by gender (Table 3.10). All 
models included UCd, which was significantly associated with all renal markers in both males 
and females. In the B2MG model, white blood cell count (WBC) and presence of DM were 
significant predictors in females only. Presence of urinary stones is a significant predictor of 
B2MG in males only. Age was significantly associated with B2MG in both males and females. 
In the NAG model, WBC and DM were significant predictors in females only. Presence of 
urinary stones was a significant predictor of NAG in both males and females. In the SCr model, 
age had similar magnitudes of association in both males and females, but the association was 
only significant in males. There was a significant association of WBC with SCr in females only 
and DM was associated with SCr in males only.   
 
Causal Mediation combining methylation markers with best-fit markers 
 Causal mediation analysis was used to establish if methylation of these markers fall 
on the causal pathway between Cd exposure and renal dysfunction. UCd was significantly 
associated with all renal biomarkers in the total population. However, the only methylation 
marker that was significantly associated with UCd was MGMT. Testing this marker for 
significance in the presence of UCd with each renal biomarker revealed no significant 
association of MGMT with any renal biomarker. Therefore, no potential mediators were found to 
be tested in the whole population. This analysis was repeated stratifying by gender. LINE-1 
methylation was found to be a potential mediator for the effects of UCd on B2MG and SCr 
levels in men. MT2A was a potential mediator of the effect of UCd on NAG levels in women. 
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 Mediation analyses testing the indirect effect of the potential mediators are shown 
in Figure 3.4. For mediation of LINE-1 with B2MG, the estimated ACME is statistically 
different from zero as are the estimated average direct (ADE) and total effects (Fig 3.4a). 
Therefore, we find that LINE-1 methylation slightly mediated the effect of urinary Cd on B2MG 
in males. This effect, however, was small with a point estimate of 0.07 and p-value of 0.04, 
while the effect of urinary Cd on B2MG is comparatively larger (β=0.93; p-value<0.001). For 
mediation of LINE-1 with SCr, the estimated ACME is not statistically significant, but the 
estimated ADE and total effects are, although the effect estimates are small (β=0.056, p-
value<0.001; β=0.063, p-value<0.001, respectively). Therefore, we find that LINE-1 methylation 
is not a mediator of the effect of urinary Cd on SCr in males. Mediation testing for MT2A with 
NAG revealed that only the ADE and total effects are significant (Fig 3.4b). Therefore, MT2A is 
not a mediator of the effect of urinary Cd on NAG in females.  
 
DISCUSSION 
The toxic effects of environmental Cd exposure have been studied as early as the 1960s 
with the outbreak of itai-itai disease in Japan. Since then, Cd has been shown to have a variety of 
adverse effects on human health, the most notable being proximal tubular renal dysfunction and 
bone disorders, such as osteomalacia and osteoporosis9, 12, 44, 50, 57, 58.  However, the pathway by 
which Cd induces these health outcomes is unknown.  
Our study shows the expected differences in UCd and renal biomarkers between groups 
with high and little to no environmental Cd exposure. The exposed group has significantly higher 
levels of UCd and renal markers compared to the unexposed group. Although our unexposed 
population had higher UCd levels (mean: 1.04 µg/L) , compared to the US population (mean: 
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0.25 µg/L)59-61, this group provides a good control to measure Cd exposure in demographically 
similar Thai populations.  
 We report sex-specific differences in UCd and renal biomarkers based on exposure 
group. Women living in the unexposed area had higher levels of UCd, but lower levels of all 
renal biomarkers, compared to men in the same area. Although the area is defined as unexposed, 
there is likely some source of Cd exposure at very low concentrations. Women, especially those 
with low iron stores, tend have higher body burdens of Cd as compared to males, regardless of 
exposure levels45, 46. Within those living in high Cd-exposed areas, women had lower levels of 
UCd and renal biomarkers as compared to men living in the same area. This is potentially due to 
the large proportion of male smokers living in Cd-exposed areas, since cadmium is found in 
tobacco.  
We also report differences in methylation markers by exposure group and sex and 
identified sex-specific associations between an IQR increase in UCd and DNA methylation. 
LINE-1 methylation was higher in exposed males compared to exposed females and we found 
that LINE-1 methylation increased with higher levels of UCd in men. These results corroborate 
literature that shows that, in general, men tend to have higher methylation of LINE-1 compared 
to women, even in the presence of cadmium exposure62. In the total population we found 
significantly lower levels of MGMT methylation in the exposed group, indicating Cd exposure 
may induce hypomethylation of this DNA repair gene. By sex, we observed MGMT methylation 
to be significantly hypomethylated in exposed males and females compared to unexposed males 
and females, respectively. We found an inverse relationship between Cd exposure and MGMT 
methylation in the total population and men specifically, which supports the hypothesis that Cd-
induced oxidative stress can lead to DNA strand breaks, leading to activation of MGMT as it is a 
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DNA repair gene that targets damage induced by oxidative stress63, 64. As Cd exposure increases, 
methylation of this gene decreases; potentially making it available for transcription. DNMT was 
significantly hypermethylated in women compared to men within the unexposed group and we 
found that DNMT methylation decreased with an IQR increase in UCd in women. Our findings 
support in vitro studies that found hypomethylation of this gene and consequent 
overexpression23, 65 as well as a previous human study conducted on environmentally-exposed 
Argentinian women49. In women, an increase in Cd exposure is associated with a decrease in 
MT2A methylation. MT2A encodes metallothionein, a protein that binds free Cd and sequesters it 
in the liver and kidney. Women tend to have higher body burden of Cd compared to men and this 
points to a potential mechanism of increased MT2A expression by which women may sequester 
larger amounts for longer periods of time. 
Several methylation markers associated with UCd were also found to be associated with 
renal biomarkers. These renal biomarkers are all significantly associated with UCd and are used 
as clinical parameters to diagnose renal tubular dysfunction, a well-known health outcome of Cd 
exposure. β2MG is the most common marker used to detect renal dysfunction. It is found on the 
surface of white blood cells and is readily filtered through the glomerulus and reabsorbed 
through the proximal tubules. In renal tubular dysfunction, β2MG is not reabsorbed and is 
excreted in the urine in high amounts. NAG is a lysosomal enzyme found in high concentrations 
in renal proximal tubular cells. Upon renal tubular damage, this enzyme is released and excreted 
in high amounts in the urine. High levels of creatinine in the serum are indicative of defects in 
glomerular filtration rate, a symptom of renal dysfunction.  
In men, LINE-1 methylation was associated with UCd and with all three of these renal 
markers, β2MG, NAG, and SCr, indicating this retroposon may play a role in the mechanism 
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between Cd exposure and renal dysfunction. DNMT methylation was significantly higher in 
exposed males compared to unexposed males, but the lack of association with UCd and any renal 
markers among males suggests that DNMT methylation in men may be related to factors other 
than Cd exposure. MT2A methylation was not associated with UCd in males, but it was 
associated with β2MG and NAG, indicating it might be useful as a marker of renal dysfunction 
only. Conversely, MGMT methylation was associated with UCd and β2MG in males, suggesting 
it may fall along the pathway of cadmium toxicity. In women, MT2A methylation was inversely 
associated with NAG, while DNMT methylation was inversely associated with both β2MG and 
SCr. Methylation of both of these genes decreased with increasing levels of UCd, and may be 
related to renal tubular damage in women. MGMT methylation was also associated with SCr in 
women only, suggesting it may be related to renal glomerular alteration.  
The sex differences in methylation markers may be indicative of the sex-specific 
differences in pathways of Cd toxicity, which is best demonstrated by the itai-itai disease 
outbreak from severe Cd poisoning in Japan. Out of 195 victims officially diagnosed with itai-
itai disease between 1967 and 2008, only three were male66.  Itai-itai disease is characterized by 
osteomalacia and renal tubular dysfunction, which may be exacerbated in women through 
physiological changes such as pregnancy and menopause67, 68. Women have a higher probability 
of developing iron deficiency and, since the method of uptake of Cd is similar to iron, they 
accumulate higher body burdens69.  Although specific mechanisms are unknown, female risk 
factors such as increased gut absorption, skeletal changes during pregnancy and menopause, and 
variation in estrogen levels may play a role in exacerbating the toxic effects of Cd exposure46, 68. 
Additionally, the differences seen in smoking status by sex may also induce gender differences. 
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 Mediation analysis in this study showed that only LINE-1 was a causal mediator of 
the effect of Cd on B2MG, although the effect estimate was small. A limitation of causal 
mediation analysis is that it tests for direct causality. Knowing that biological mechanisms rarely 
involve only one marker, it is necessary to look at multiple markers involved in the same or 
similar mechanisms and assess them as multiple mediators. Previous literature has shown 
epigenetic aberration of genes such as hMSH2, ERCC1, XRCC1, hOGG1, in response to Cd and 
our study adds to this by the significant differences seen in the methylation of markers by 
exposure group and gender. A more likely scenario to consider when assessing epigenetic 
changes in response to Cd exposure would be to assess multiple mediators along the pathway of 
Cd exposure and adverse health outcomes (Figure 3.5).  
 Specific gravity (SG) was used to adjust urinary biomarker levels for dilution 
effects since creatinine is a clinical parameter of renal dysfunction and has been shown to be 
inversely correlated with Cd measurements in the soil70-72. To avoid potential bias, individual 
urinary biomarkers were standardized to the median SG of the unexposed population only.  
The association of methylation markers with UCd and renal biomarkers implicates 
aberrant methylation of these genes in the pathogenesis of Cd exposure to renal dysfunction and 
potentially to cancer. These relationships are sex-specific, and suggest that the pathway of 
exposure to disease may differ by sex. A limitation of this cross-sectional study is that it was not 
able to assess cancer as a health outcome. This limitation was addressed by using renal 
dysfunction as a proxy since Cd exposure levels associated with kidney effects and various 
cancers are similar (Table 3.2; Table 3.3). Other limitations include lack of dietary information 
and measurements of other metals that may confound the results presented here.  
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CONCLUSIONS  
Much of what is known about the mechanism behind Cd toxicity is from animal models 
or in vitro cellular experiments. Our study utilizes a population with a wide range of relevant Cd 
levels and extensively characterized methylation biomarkers. To our knowledge, this is the first 
study to examine such ranges within the context of DNA methylation in a population-based 
study. As with many epigenetic epidemiology studies, we were limited to measuring methylation 
in circulating cells from blood. As such, the conclusions we can draw regarding the direct effects 
of Cd on epigenetic may not be extrapolated to relevant tissues, such as the kidneys and liver. 
However, studies such as these are a logical first step to identifying the mechanisms of Cd 
toxicity, and may identify useful biomarkers that indicate underlying health consequences of Cd 
exposure.  
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Table 3.1. Key Molecular Studies in Determining Potential Mechanisms of Actions of 
Cadmium in Carcinogenesis 
Model Dose Duration Results References 
TRL 1215 rat liver 
cells 
1.0 and 
2.5uM 
1 week and 
10 weeks 
Inhibited DNMT activity and global DNA 
hypomethylation at 1 week, enhanced DNMT 
activity and global DNA hypermethylation at 
10 weeks 
Takiguchi et 
al., 200365 
Human embryo 
lung fibroblasts 
1.2 and 
1.5uM 
2 months 
Concentration-dependent hypermethylation of 
DNA. Correlated with increased DNMT 
activity and overexpression of DNMT1, 
DNMT3a and DNMT3b 
Jiang et al., 
200831 
Chronic 
myelogenous 
leukemia K562 
cells 
2.0uM 
24 & 48 
hours 
Global hypomethylation of DNA 
Huang et al, 
200832 
Human breast 
epithelial cell line 
MCF-10A 
2.5 
µM 
40 weeks 
Malignant transformation to basal-like breast 
carcinoma cells. Global DNA 
hypomethylation, c-myc and k-ras 
overexpression, reduced BRCA1 expression, 
increased CK5 and p63 expression 
Benbrahim-
Tallaa et al., 
200922 
Human prostate 
epithelial cells 
10uM 10 weeks 
Malignant transformation of cells, global 
DNA hypomethylation , overexpression of 
DNMT3b, promoter hypermethylation and 
reduced expression of RASSF1A and p16 
tumor suppressor genes 
Benbrahim-
Tallaa et al., 
200723 
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Table 3.2. Exposure levels associated with cancer. 
Cancer/study population, reference Exposure/risk estimate 
Lung, Belgium, n = 994, 15-year 
observation73 
Hazard ratios of 1.7, 2.6, and 1.6 were attributed to a 2-fold 
increase in body burden, living in high-exposure area, and a 
2-fold increase in soil cadmium, respectively. 
Pancreas, Egypt, n = 31 cases, 52 controls74 ORs of 1.12 and 3.25 were attributed to elevated serum 
cadmium and farming occupation, respectively. 
Breast, United States, n = 246 cases, 254 
controls19 
OR of 2.3 when comparing urinary cadmium < 0.26 versus 
≥ 0.58 µg/g creatinine 
Endometrium, Sweden, n = 30,210, 16-year 
observation70 
OR of 2.9 was attributed to cadmium intake > 15 µg/day. 
Prostate, China; n = 29775 Dose response between body burden and abnormal serum 
PSA levels 
Prostate, Italy, n = 45 cases, 58 controls76 OR of 4.7 when comparing nail cadmium content in the 
lowest versus the highest quartile 
Prostate, United States, n = 42277 An increase of urinary cadmium to 1 µg/g creatinine 
associated with a 35% increase in serum PSA 
Urinary bladder, Belgium, n = 172 cases, 395 
controls78 
OR of 5.7 when comparing blood cadmium in the lowest 
versus the highest tertile 
Abbreviations: OR, odds ratio; PSA, prostate-specific antigen. 
Table adapted from Satarug, et al, Environ Health Perspect. Feb 2010; 118(2): 182–19079 
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Table 3.3. Exposure levels associated with kidney and bone effects. 
Study population, age, reference Exposure/outcomes 
Sweden, n = 820, 53–64 years of age70, 80 Blood and urinary cadmium at 0.38 µg/L and 0.67 µg/g 
creatinine were associated with tubular impairment. Urinary 
cadmium at 0.8 µg/g creatinine was associated with 
glomerular impairment. Increased body burden of cadmium 
was associated with lowered bone mineral density, 
decreased serum parathyroid hormone and bone 
metabolism. 
Thailand, n = 200, 16–60 years of age81 A 3-fold increase in body burden associated with 11%, 
32%, and 61% increases the probability of having high 
blood pressure, renal injury, and tubular impairment. 
Thailand, n = 224, 30–87 years of age82 OR for tubular impairment was 10.6, comparing urinary 
cadmium 1–5 versus > 5 µg/g creatinine. 
United States, n = 4,258, ≥ 50 years of age83 A 1.43-fold increase in osteoporosis risk, comparing urinary 
cadmium 1 versus < 0.5 µg/g creatinine 
Belgium, n = 294, mean age 49.2 years of 
age84 
A 2-fold increase in body burden associated with increased 
bone resorption, urinary calcium loss, decreased proximal 
forearm bone density, and low serum parathyroid hormone. 
China, n = 148, 3-year observation85 Progressive tubular and glomerular impairment was 
observed among those with urinary cadmium > 10 µg/g 
creatinine. 
United Kingdom, n = 160, 18–86 years of 
age86 
Risk for early renal effectsa was increased by 2.6-fold and 
3.6-fold, comparing urinary cadmium 0.3 versus < 0.5 
versus ≥ 0.5 µg/g creatinine. 
United States, n = 14,778, > 20 years of age6 Risk for albuminuria was 2.34 and risk for lowered 
glomerular filtration rate was 1.98, comparing those in the 
highest versus lowest quartiles of blood cadmium and lead. 
Abbreviations: OR, odds ratio 
aEarly renal injury was defined as urinary NAG > 2 IU/g creatinine. 
Table adapted from Satarug, et al, Environ Health Perspect. Feb 2010; 118(2): 182–19079 
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Table 3.4. Descriptive Statistics of Study Population  
  Unexposed  
(n=100) 
Exposed        
(n=169) 
  
  Mean (SD) Mean (SD) p-value 
Age (years) 61.0 (11.5) 61.2 (11.8) 0.93 
  Median (IQR) Median (IQR) p-value 
UCd (µg/L) 1.0 (0.65, 1.60) 7.4 (4.4, 10.2) <0.001 
Specific Gravity 1.017 (1.013, 1.020) 1.014 (1.011, 1.018) 0.01 
β2MG (µg/L) 235.3(98.6, 411.2) 1171.3 (199.0, 6715.0) <0.001 
NAG (U/L) 5.54 (3.7, 9.4) 8.84 (5.2, 12.7) 0.0002 
SCr (mg/dL) 0.9 (0.8, 1.1) 1.1 (0.9, 1.3) <0.001 
UCr (g/L) 1.3 (1.0, 1.6) 1.4 (1.1, 1.7) 0.08 
LINE-1 (%) 82.5 (79.0, 81.1) 80.2 (79.4, 81.1) 0.87 
MT2A (%) 23.2 (20.9, 28.8) 23.1 (20.8, 25.0) 0.1 
DNMT (%) 1.4 (1.1, 1.9) 1.4 (1.2, 1.9) 0.78 
MGMT (%) 2.3 (1.8, 3.1) 1.7 (1.4, 2.1) <0.001 
WBC (10^3cells/uL) 8.4 (6.9, 9.9) 8.3 (6.9, 9.9) 0.57 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: UCd (urinary cadmium); β2MG (β2-microglobulin); NAG (N-acetyl-beta-D-glucosaminidase);SCr (serum  
creatinine); WBC (white blood cell); n (number of subjects); SD (standard deviation); IQR (Interquartile Range). 
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Table 3.5. Demographics of Study Population 
                             Unexposed 
                           (n=100) 
Exposed  
(n=169) 
  All Male Female All Male Female 
Smoking N (%) N (%) N (%) N (%) N (%) N (%) 
      
Never 36 (36) 6 (12) 30 (60) 66 (39.1) 11 (13.3) 55 (64) 
Former 33 (33) 21 (42) 12 (24) 32 (18.9) 17 (20.5) 15 (17.4) 
Regular 31 (31) 23 (46) 8 (16) 71 (42.0) 55 (66.3) 16 (18.6) 
Diabetes Mellitus (DM)        
No 88 (88) 45 (90) 43 (86) 158 (93.5) 80 (96.4) 78 (90.7) 
Yes 12 (12) 5 (10) 7 (14) 11 (6.5) 3 (3.6) 8 (9.3) 
Hypertension (HT)        
No 61 (61) 29 (58) 32 (64) 93 (55) 49 (59) 44 (51.2) 
Yes 39 (39) 21 (42) 18 (36) 76 (45) 34 (41) 42 (48.8) 
Urinary Stones        
No 95 (95) 47 (94) 48 (96) 140 (82.8) 68 (81.9) 72 (83.7) 
Yes 5 (5) 3 (6) 2 (4) 29 (17.2) 15 (18.1) 14 (16.3) 
Drinker        
Never 50 (50) 6 (12) 44 (88) 82 (48.5) 19 (22.9) 63 (73.3) 
Former 26 (26) 23 (46) 3 (6) 33 (19.5) 22 (26.5) 11 (12.8) 
Regular 24 (24) 21 (42) 3 (6) 54 (32.0) 42 (50.6) 12 (14) 
Occupation        
Agriculture 74 (74) 36 (72) 38 (76) 85 (50.3) 51 (61.4) 34 (39.5) 
Other 26 (26) 14 (28) 12 (24) 84 (49.7) 32 (38.6) 52 (60.5) 
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Abbreviations: UCd (urinary cadmium); β2MG (β2-microglobulin); NAG (N-acetyl-beta-D-glucosaminidase);SCr (serum creatinine); WBC (white blood cell); n (number of subjects); SD (standard 
deviation); IQR (Interquartile Range); M (males); F (females). p-values are given for comparisons between males and females within the aunexposed group, bexposed group, and between exposure 
groups within cmales and  dfemales. 
 
 
 
 
Table 3.6. Descriptive Statistics of Study Population by Sex 
  Unexposed 
(n=100) 
Exposed 
(n=169) 
    
  Male  
(n=50) 
Female  
(n=50) 
p-valuea Male  
(n=83) 
Female  
(n=86) 
p-valueb p-valuec 
(M) 
p-valued 
(F) 
  Mean (SD) Mean (SD)   Mean (SD) Mean (SD)      
Age (years) 62.5 (12.1)  0.21 62.7 (11.7) 59.7 (11.8) 0.09 0.91 0.96 
  Median (IQR) Median (IQR)   Median (IQR) Median (IQR)      
UCd (µg/L) 0.9 (0.5, 1.2) 1.4 (0.9, 2.0) <0.001 8.0 (5.2, 10.5) 6.4 (3.6, 9.5) 0.04 <0.001 <0.001 
Specific Gravity   1.018 (1.013, 1.019)    1.016 (1.012, 1.020) 0.3 1.014 (1.012, 1.019)   1.014 (1.011, 1.017) 0.12 0.08 0.08 
β2MG (µg/L)   277.2 (133.7, 678.5)   164.1 (87.1, 315.6) 0.03 1434.4 (269.8, 6323.1)   735.6 (154.8, 7073.8) 0.5 <0.001 <0.001 
NAG (U/L) 5.7 (4.5, 10.4) 5.4 (3.4, 7.4) 0.12 9.8 (6.8, 13.5) 7.8 (4.6, 12.5) 0.03 0.003 0.02 
SCr (mg/dL) 1.0 (0.9, 1.1) 0.8 (0.8, 1.3) <0.001 1.2 (1.0, 1.3) 1.0 (0.8, 1.2) <0.001 0.001 0.0002 
UCr (g/L) 1.3 (1.2, 1.6) 1.1 (1.0, 1.5) 0.003 1.4 (1.2, 1.8) 1.3 (1.0, 1.6) 0.008 0.33 0.08 
LINE-1 (%) 80.6 (79.0, 81.1) 80.4 (79.0, 81.2) 0.64 80.4 (79.7, 81.4) 79.7 (78.9, 80.7) 0.001 0.18 0.4 
MT2A (%) 22.8 (20.7, 24.9) 23.8 (21.5, 26.2) 0.09 22.7 (20.7, 24.4) 23.5 (21.0, 25.5) 0.69 0.65 0.06 
DNMT (%) 1.3 (0.9, 1.8) 1.7 (1.3, 2.1) 0.008 1.5 (1.2, 1.9) 1.4 (1.2, 1.9) 0.66 0.03 0.08 
MGMT (%) 2.4 (2.0, 3.4) 2.2 (1.7, 2.7) 0.22 1.6 (1.3, 2.2) 1.7 (1.4, 2.0) 0.91 0.0002 0.003 
WBC (10^3cells/uL) 8.7 (7.0, 9.9) 8.3 (6.8, 10.4) 0.74 8.5 (7.2, 10.3) 8.1 (6.9, 9.8) 0.13 0.92 0.37 
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Table 3.7. Associations between Urinary Cadmium, Methylation 
and Renal Markers 
    Urinary Cadmium (µg/L)a 
   All Men Women 
  N IQR Change (95% CI) IQR Change (95% CI) IQR Change (95% CI) 
LINE-1c 259 0.5 (-0.3, 1.2) 0.9 (0, 1.7) 0.03 (-0.9, 0.9) 
MT2Ac 269 -3.2 (-9.2, 3.2) 1.3 (-10.9, 15.2) -7.4 (-12.9, -1.7) 
DNMTc 264 -1.8 (-8.6, 5.5) 2.2 (-10.1, 16.2) -8.5 (-16.1, -0.1) 
MGMTc 226 -16.6 (-25.1, -7.2) -24.7 (-36.5, -10.7) -8.9 (-19.3, 2.9) 
   β2MG (µg/L)b 
   All Men Women 
  N Change (95% CI)d Change (95% CI) Change (95% CI) 
UCdc 269 1044.6 (646.2, 1655.9) 1130.7 (547.8, 2238.1) 1090.3 (548.8, 2083.6) 
LINE-1d 259 15.1 (3.3, 79.9) 32.7 (13, 158.1) 2.7 (-11.8, 26) 
MT2Ad 269 0.4 (-0.6, 32.3) 1.4 (0.3, 53.4) -1.4 (-3.1, 5.8) 
DNMTd 264 -0.9 (-1.8, 1) -0.3 (-1.5, 60.3) -1.5 (-2.8, -3.1) 
MGMTd 226 -0.8 (-1.5, -8.2) -0.9 (-1.7, -3.4) -0.7 (-1.9, 23.3) 
   NAG (U/L)b 
   All Men Women 
  N IQR Change (95% CI) IQR Change (95% CI) IQR Change (95% CI) 
UCdc 269 60.5 (39.1, 85.1) 65.2 (33.4, 104.6) 61.6 (34.7, 93.8) 
LINE-1d 259 4.0 (0.9, 7.3) 5.1 (0.4, 10) 2.5 (-1.8, 7) 
MT2Ad 269 -0.04 (-0.3, 0.2) 0.3 (0, 0.6) -0.7 (-1.1, -0.2) 
DNMTd 264 0.05 (-0.2, 0.3) 0.2 (-0.2, 0.5) -0.004 (-0.4, 0.4) 
MGMTd 226 -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.2) -0.1 (-0.4, 0.2) 
   Serum Creatinine (mg/dL) b 
   All Men Women 
  N IQR Change (95% CI) IQR Change (95% CI) IQR Change (95% CI) 
UCdc 269 13.6 (9.6, 17.7) 16.5 (7, 26.9) 11.4 (4.9, 18.4) 
LINE-1d 259 1.2 (0.1, 2.3) 2.5 (1, 4.1) 0.1 (-1.4, 1.6) 
MT2Ad 269 0.01 (-0.1, 0.1) 0.05 (0, 0.1) 0 (-0.2, 0.1) 
DNMTd 264 -0.1 (-0.2, 0.02) -0.01 (-0.1, 0.11) -0.1 (-0.3, 0) 
MGMTd 226 -0.1 (-0.1, -0.01) -0.1 (-0.1, 0.01) -0.1 (-0.2, -0.01) 
apredictor ;  boutcome; cPercent change associated with IQR increase in UCd ;  dPercent change in renal marker level with a 
1% increase in methylation; *All variables except age log-transformed; **all models are adjusted by age 
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Abbreviations: UCd (urinary cadmium); β2MG (β2-microglobulin); NAG (N-acetyl-beta-D-glucosaminidase);SCr (serum creatinine); WBC (white blood cell); N (number of subjects); SE (standard 
error); Hgb (hemoglobin levels); DM (diabetes mellitus); HT (hypertension);   
Table 3.8. Best-fit Models for Exposed and Unexposed Populations 
  UNEXPOSED 
N=100 
EXPOSED 
N=169 
 Predictors β2MG(µg/L) NAG(U/L) SCr (mg/dL) β2MG(µg/L) NAG(U/L) SCr (mg/dL) 
 β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p 
UCd (µg/L) 
  0.28 (0.19) 0.14   1.77 (0.22) <0.001 0.46 (0.06) <0.001 0.07 (0.03) 0.02 
Age (years) 0.05 (0.01) <0.001 0.02 (0.005) 0.002 0.003 (0.0006) <0.001 0.07 (0.01) <0.001 0.01 (0.003) <0.001 0.004 (0.001) 0.01 
Former 
Smoker 0.82 (0.29) 0.006         0.04 (0.05) 0.39 
Regular 
Smoker 0.46 (0.28) 0.1         -0.07 (0.04) 0.09 
Former 
Drinker             
Regular 
Drinker             
Male 
  0.24 (0.12) 0.05 0.10 (0.01) <0.001     0.12 (0.04) 0.003 
WBC 
(10^3cells/uL) 1.16 (0.45) 0.01     1.36 (0.49) 0.006 0.50 (0.12) <0.001 0.14 (0.06) 0.02 
Hgb 
      -0.20 (0.08) 0.01   -0.02 (0.01) 0.11 
DM 0.97 (0.36) 0.008 0.53 (0.17) 0.002   1.07 (0.52) 0.04   0.27 (0.06) <0.001 
HT 
      0.60 (0.27) 0.03     
Urinary Stone 
      0.93 (0.33) 0.005 0.28 (0.08) <0.001 0.07 (0.04) 0.07 
AIC 316.6 170.7 -254.3 649.2 182 -58.7 
AdjR2 0.3692 0.18 0.4826 0.5325 0.4689 0.272 
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
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Abbreviations: UCd (urinary cadmium); β2MG (β2-microglobulin); NAG (N-acetyl-beta-D-glucosaminidase);SCr (serum creatinine); WBC (white 
blood cell); N (number of subjects); SE (standard error); Hgb (hemoglobin levels); DM (diabetes mellitus); HT (hypertension);   
  
Table 3.9. Combined predictors from both Populations 
  β2MG(µg/L) NAG(U/L) SCr(mg/dL) 
Predictors β (SE) p-value β (SE) p-value β (SE) p-value 
UCd (µg/L) 1.30 (0.13) <0.001 0.27 (0.04) <0.001 0.07 (0.01) <0.001 
Age (years) 0.06 (0.009) <0.001 0.02 (0.003) <0.001 0.003 (0.001) <0.001 
Former Smoker 0.38 (0.26) 0.14   0.01 (0.03) 0.64 
Regular Smoker 
0.19 (0.23) 0.41   -0.06 (0.03) 0.04 
Former Drinker 
      
Regular Drinker 
      
Male 
  0.13 (0.06) 0.03 0.12 (0.03) <0.001 
WBC 
(10^3cells/uL 1.20 (0.37) 0.001 0.37 (0.11) <0.001 0.10 (0.04) 0.02 
Hgb -0.13 (0.06) 0.05   -0.01 (0.008) 0.05 
DM 1.11 (0.34) 0.001 0.34 (0.10) 0.001 0.13 (0.04) <0.001 
HT 0.52 (0.20) 0.01 0.27 (0.09) 0.002   
Urinary Stone 0.88 (0.28) 0.002   0.06 (0.03) 0.08 
AdjR2 0.5314 0.35 0.2728 
p-value <0.001 <0.001 <0.001 
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Abbreviations: UCd (urinary cadmium); β2MG (β2-microglobulin); NAG (N-acetyl-beta-D-glucosaminidase);SCr (serum creatinine); WBC (white blood cell); N (number of subjects); SE (standard error); Hgb (hemoglobin 
levels); DM (diabetes mellitus); HT (hypertension);   
Table 10. Combined Predictors from both Populations Stratified by Gender 
 Males  
N=133 
Females  
N=136 
  β2MG NAG SCr β2MG NAG SCr 
Predictors β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p β (SE) p 
UCd 1.05 (0.16) <0.001 0.22 (0.05) <0.001 0.07 (0.02) <0.001 1.59 (0.20) <0.001 0.33 (0.06) <0.001 0.07 (0.02) 0.003 
Age 0.04 (0.01) 0.001 0.01 (0.004) <0.001 0.003 (0.001) 0.007 0.09 (0.01) <0.001 0.01 (0.004) 0.002 0.003 (0.002) 0.14 
Former 
Smoker 0.46 (0.44) 0.29   0.05 (0.04) 0.23 -0.18 (0.37) 0.63   0.002 (0.05) 0.97 
Regular 
Smoker 0.07 (0.40) 0.87   -0.02 (0.04) 0.54 0.14 (0.37) 0.71   -0.05 (0.04) 0.27 
Former 
Drinker             
Regular 
Drinker             
Male 
            
WBC 0.97 (0.55) 0.08 0.31 (0.17) 0.07 0.06 (0.05) 0.27 1.57 (0.51) 0.002 0.43 (0.16) 0.007 0.14 (0.06) 0.03 
Hgb -0.17 
(0.09) 0.05   -0.009 (0.009) 0.28 -0.17 (0.11) 0.12   -0.02 (0.01) 0.11 
DM 0.98 (0.55) 0.08 0.14 (0.17) 0.42 0.24 (0.05) <0.001 1.27 (0.43) 0.004 0.43 (0.13) 0.002 0.06 (0.05) 0.26 
HT 0.45 (0.29) 0.12 0.002 (0.09) 0.98 0.05 (0.03) 0.07 0.50 (0.29) 0.08 0.12 (0.09) 0.2 -0.007 (0.04) 0.83 
Urinary 
Stone 0.98 (0.38) 0.01 0.25 (0.12) 0.04 0.06 (0.04) 0.11 0.88 (0.44) 0.05 0.29 (0.14) 0.03 0.03 (0.05) 0.64 
AdjR2 0.4764 0.2729 0.3855 0.5892 0.3849 0.1181 
p-value <0.001 <0.001 <0.001 <0.001 <0.001 0.002 
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Figure 3.1 Map of Thailand. Mae Sot District is marked (red star) 
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Figure 3.2. Mediation Analysis. The total effect of the independent variable (IV) is calculated on the 
dependent variable (DV) alone. Then the Average Direct Effect (ADE) of the IV on DV is calculated with 
the potential mediator in the model. The average causal mediation effects (ACME) are calculated to 
determine the effect the mediator has on the relationship between the IV and DV. Adding the ACME and 
the ADE gives the total effect. 
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Figure 3.3. Percent change for each methylation marker per IQR increase in urinary Cd for the total 
population and by sex.  In the total population, MGMT methylation decreases with an IQR increase in 
urinary Cd (purple). In males, an IQR increase in urinary Cd is associated with an increase in LINE-1 and 
a decrease in MGMT methylation (light blue). In females, an IQR increase in urinary Cd is associated 
with a decrease in MT2A and DNMT methylation (dark blue). 
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Figure 3.4. Mediation analysis. a) Males. LINE-1 is a mediator of the effects of Cd on B2MG (black), but 
not of the effects of Cd on blood creatinine (red) b) Females. No mediators were found.  
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Figure 3.5. A better way to assess mediation along the pathway from Cd exposure to adverse health 
outcomes would be to consider multiple mediators as biological mechanisms rarely involve only one 
marker 
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CHAPTER 4 
Gene Methylation markers are associated with recurrence and survival 
in patients with head and neck squamous cell carcinoma 
 
ABSTRACT 
Background: The overall 5-year survival rate of head and neck squamous cell carcinoma 
(HNSCC) has remained at about 50-60% for the past decade, primarily due to loco-regional or 
metastatic recurrence. HPV-associated HNSCCs have a unique risk profile, clear etiologic 
mechanism, and an improved prognosis as compared to non-HPV associated HNSCCs. 
However, even within the HPV+ group, there is heterogeneity in survival time, with up to 20% 
progressing with distant metastases. Thus, there is strong interest in identifying prognostic 
markers in these patients related to tumor biology and epidemiologic characteristics. 
Methods: Six gene methylation markers were analyzed using DNA extracted from previously 
untreated tumor tissue collected from a well-characterized, unselected cohort of HNSCC patients 
at the University of Michigan. Survival analysis was conducted to determine the association of 
these markers with overall survival time and recurrence-free survival time using Kaplan-Meier 
curves and stratified Cox proportional hazards models. 
Results: In the multivariable Cox proportional hazards model, those with low methylation of 
NDN and CD1A had 1.6 and 1.3 times the odds of a death event, respectively (p <0.01; p <0.05, 
respectively). Multivariable Cox models stratified by HPV status revealed that HPV+ patients 
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with low methylation of CD1A had 3.3 times higher odds of a death event and 2.1 times higher 
odds of a recurrence event (p <0.01, p <0.01) . However, the same patients with low CCNA1 
methylation had 0.31 times lower odds of a recurrence event (p <0.05). HPV- patients with low 
NDN methylation had 1.6 times higher odds of a death event (p <0.05).  
Conclusions: The novel methylation markers identified in this study offer new, specific, 
epigenetic molecular differences within the setting of the generalized hypermethylation 
phenotype associated with HPV status and warrant further investigation.  The findings support 
biological implications of epigenetic markers on patient survival and their potential clinical 
utility in identifying unique subsets of patients with varied outcomes. 
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INTRODUCTION 
Head and neck cancer is the 6th most common cancer in the world with at least 90% being 
squamous cell carcinomas and approximately 600,000 new cases each year 1-3. Sites of the head 
and neck are shown in Figure 4.1. Heavy tobacco and alcohol use are well established risk 
factors but more recently human papilloma virus (HPV) infection has been identified as a new 
etiologic factor for head and neck squamous cell carcinomas (HNSCCs). The overall 5-year 
survival rate has remained at about 50-60% for the past decade, primarily due to loco-regional or 
metastatic recurrence, which present in 35% to 55% of patients within two years (Figure 4.2)1, 4. 
This is partially due to the fact that almost 60% of patients are diagnosed after the disease has 
locally advanced, but also due to pathological, clinical and epidemiological heterogeneity5, 6 and 
frequent association of significant co-morbidities. 
The incidence of HPV-associated HNSCC has steadily increased, especially in younger 
patients, while incidence of non-HPV associated HNSCC has declined in recent years7, 8. HPV-
associated HNSCCs have a unique risk profile, clear etiologic mechanism, and an improved 
prognosis as compared to non-HPV associated HNSCCs7, 9-14. HPV+ patients tend to have 
cancers almost exclusively located in the oropharynx, to be younger, with a higher 
socioeconomic status and a less profound use of alcohol and tobacco12, 15, 16. Studies show a 60-
80% reduction in mortality in HPV+ patients compared to patients with non-HPV associated 
HNSCC17-19 regardless of treatment modality or tumor stage (Figure 4.3). Even within the HPV+ 
group, however, there is heterogeneity in survival time, with up to 20% progressing with distant 
metastases. Distinct patterns of chromosomal aberrations and copy number variation have been 
found to be associated with shorter survival times 20, 21. Changes in gene expression patterns of 
tumor suppressors and oncogenes have been used to classify subtypes of HNSCC with improved 
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prognosis22-24.  Thus, there is strong interest in identifying potential prognostic markers for 
patients with HNSCC.  A useful approach would be use epigenetic factors, particularly for DNA 
methylation, as prognostic markers. CpG methylation changes precede genetic aberrations and 
gene expression, providing an underlying mechanism for tumor heterogeneity.   
 It has been demonstrated that epigenetic alterations are part of the causal pathway 
in tumorigenesis25. Aberrant methylation profiles have implicated the involvement of many 
genes in the development and progression of HNSCC. Changes in methylation have been found 
in genes involved in various pathways including cell cycle control26-28, signal transduction22, 26, 29-
32, apoptosis26, 33, cell-cell adhesion33, 34, immune response35, 36, and epithelial-mesenchymal 
transition28, 37 pathways.  Some of these findings have been extended to propose prognostic 
markers using discovery-based27, 38, 39 or candidate gene based approaches28, 30. However, these 
studies have a limited ability to detect strong survival associations due to small sample sizes. 
Large sample cohorts with defined clinic-pathological and epidemiological characteristics are 
needed to provide reliable prognostic biomarkers40.  Combining methylation information of 
clinical characteristics known to affect survival with other biomarkers is crucial to understanding 
the differences in survival rates by these characteristics and how they may be targeted for 
intervention. Few studies have taken a comprehensive approach in observing methylation of 
prognostic biomarkers across known clinical and epidemiological indicators of survival.   
It is unclear whether the prognostic advantage of HPV-associated tumors is due to tumor 
biology, epidemiologic characteristics, or a combination of the two. Our group recently 
completed a discovery-based approach to determine novel prognostic epigenetic biomarkers27 
and here we test identified markers for their association with tumor recurrence and survival.  
This takes advantage of a well-characterized, unselected cohort of HNSCC patients at the 
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University of Michigan, with extensive epidemiologic, clinical, and survival information that 
were treated by a single group of clinicians with a homogenous treatment approach. This allows 
careful consideration of the epigenetic biomarkers in the context of epidemiologic and clinico-
pathologic characteristics that also influence survival. Identification of significant epigenetic 
markers of biologic tumor behavior and outcome should open new horizons for interventions 
directed at reversible gene alterations and new therapeutic targets. 
 
METHODS 
Recruitment. The University of Michigan’s Head and Neck Specialized Program of Research 
Excellence (SPORE) approaches every incident, previously untreated head and neck squamous 
cell carcinoma (HNSCC) patient to participate in our longitudinal epidemiology studies.  This 
unselected study population represents 28% of incident HNSCC cases in the state of Michigan.  
From November 2008 through June 2012, subjects were screened for eligibility and 92% of 
subjects approached signed a written, informed consent.  After consent, 513 subjects were asked 
to complete a baseline epidemiologic questionnaire of demographics, epidemiologic 
characteristics, and behavior modules.  Research assistants collected paraffin-embedded (FFPE) 
tissue blocks and detailed pathophysiological and clinical data annually until death or lost to 
follow-up for patients with tumor of the oral cavity, oropharynx, hypopharynx and larynx.  This 
study was approved by the Institutional Review Board of the University of Michigan Medical 
School (HUM00042189). 
 
Tissue acquisition. The FFPE tissue blocks were collected from three possible sources: (1) a 
biopsy done at an outside hospital, (2) a biopsy done at the University of Michigan hospital, 
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and/or (3) a surgery done at the University of Michigan hospital.  All possible tumor specimen 
blocks were collected for each subject, except if blocks were unable to be obtained due to 
reasons of outside hospital refusal to provide blocks or a block was unavailable for research 
purposes.  Tissue acquired from the three sources yielded a possible sample for 88% of subjects.   
 
Study Population. A pathologist (JM) confirmed tumor histology and screened representative 
blocks for areas of >70% cellularity and minimal necrosis.  Tumors with insufficient histology, 
inadequate tissue, or yielded insufficient amounts of DNA for methylation assays were excluded 
from analysis.  There remained 72% of subjects who had sufficient tissue which yielded 
methylation results.  There were 15 subjects whose sites were not analyzed (unknown primary, 
nasopharynx, salivary gland, skull bones), 7 subjects with equivocal HPV status, and 1 subject 
lost to follow up.  The final count of study subjects is 346 and represents 67% of eligible 
participants screened for this analysis.   
 
Follow-up. All patients were followed prospectively at designated intervals by our clinicians in 
clinics at the University of Michigan or through contact with referring physicians.  Median 
follow period for survival was 27.4 months and for 24.9 months for recurrence. Deaths were 
captured through the Social Security Death Index, yearly survey updates, notification from 
family, and medical record reviews.  Survival time and events were censored as of 4/30/13.  
Recurrence and persistent disease events were updated annually during a chart review occurring 
at every subject’s yearly anniversary of their date of initial diagnosis.   
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Microdissection/DNA Extraction/Bisulfite Conversion. Designated areas of FFPE tissue were 
microdissected from unstained slides and DNA was extracted using the QIAamp DNA FFPE 
Tissue Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. DNA concentration 
and purity was measured with a NanoDrop spectrophotometer (Thermo Scientific, 
Waltham, MA)). Sodium bisulfite modification was performed on 250ng of DNA using the 
Epitect Bisulfite Kit ((Qiagen, Valencia, CA) according to the manufacturer’s recommended 
protocol.   
 
HPV testing. Tumor HPV status was determined by an ultrasensitive method using real-time 
competitive polymerase chain reaction and matrix-assisted laser desorption/ionization time of 
flight mass spectroscopy with separation of products on a matrix loaded silicon chip array, as 
described in Tang et al.41. Multiplex PCR amplification of the E6 region of 15 discrete high risk 
HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 73), and human 
GAPDH control was run to saturation followed by shrimp alkaline phosphatase quenching. 
Amplification reactions included a competitor oligo identical to each natural amplicon except for 
a single nucleotide difference. Probes that identify unique sequences in the oncogenic E6 region 
of each type were used in multiplex single base extension reactions extending at the single base 
difference between wild-type and competitor HPV so that each HPV type and its competitor 
were distinguished by mass when analyzed on the MALDI-TOF mass spectrometer as described 
previously42-45.  
 
Methylation Analysis. CCNA1, NDN, DCC and CD1a were chosen for further study from a 
previous analysis that found them to be differentially methylated in head and neck cancer 
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patients by HPV status 27. Methylation assays for 3 genes, DCC, CD1a, and NDN, were designed 
using PyroMark Assay Design 2.0 software. CCNA1 was sequenced using the Sequenom 
EpiTyper, a MALDI-TOF mass spectrometry based platform. Bisulfite singleplex PCR 
amplification was performed using FastStart Taq Polymerase (Roche Diagnostics, Indiana, US) 
with a forward and reverse primer concentration of 0.2 mM and 10ng/uL of bisulfite-converted 
DNA. Fifteen microliters of each PCR product was combined with the respective sequencing 
primer and methylation analysis by pyrosequencing was conducted for each assay as previously 
described46. Complete coverage of all samples for every methylation marker selected was not 
possible due to low quantity of total extracted DNA. 
 
Statistical Analysis. Univariate and bivariate analyses were conducted on all methylation markers 
and pathological and epidemiological characteristics. Kaplan-Meier analysis was employed to 
graphically visualize time-to-event outcomes for the probability of overall survival (OST) and 
recurrence-free survival time (RFT). Methylation of each marker was divided into quartiles with 
quartile 1 containing the lowest values and quartile 4 containing the highest. Statistical 
differences in curves were tested using the log-rank test.  All methylation markers except NDN 
were log-transformed due to departures from normality to satisfy model assumptions.  
Cox proportional hazard models were used to adjust for identified prognostic factors 
including patient age, tumor stage, disease site (and comorbidity score for OST), and HPV status. 
Stratified Cox proportional hazard models were used to vary the baseline hazard function by 
HPV status to account for non-constant hazards observed in our data by HPV status. Odds of a 
death or recurrence were based on methylation values standardized to the interquartile range 
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(IQR) of each respective marker. The interpretation of the hazard ratio was a comparison of 
those with methylation in the 25th percentile compared to those in the 75th percentile. 
A methylation score was calculated to create a composite measurement of methylation 
across all candidate genes. Methylation for each gene less than 10% was given a score of zero. 
The median of the remaining samples for each gene was calculated and methylation values less 
than the median were given a score of 1 while methylation values above the median were given a 
score of 2 for each gene. These scores were added up across all genes for each patient to generate 
a composite score of methylation. The composite scores were divided according to distribution 
across scores and by quartiles and analyzed by HPV status and for OST and RFT. 
 
RESULTS 
Population Characteristics   
 The mean age of the population was 59.7 years with 75% males (Table 4.1). 
Cancer sites were mostly oropharyngeal and oral cavity (36% each) while glottic cancers made 
up about 24% of cases and only 3% presented in the hypopharynx. Sixty-one percent of cases 
were stage IV and HPV(-). Most patients had mild comorbidity status (46%), while 26% had 
moderate comorbidity scores and 8% had severe scores. Forty-two percent of patients were 
classified as current smokers, having quit within the past 12 months, while 36% were former 
smokers and 22% were never smokers. Most patients were former alcohol users (66%), having 
quit greater than 12 months ago. (Table 4.1).  
Patients with HPV+ tumors were on average younger than patients with HPV(-) tumors 
(mean age = 61.4 years, SD: 12.3 years for HPV (-) patients and 57 years, SD: 9.6 years, for 
HPV (+) patients (Table 4.2). The ratio of male to female patients was more extreme in the group 
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of patients with HPV (+) tumors (89% HPV (+) male vs. 66% HPV (-) male, p-value<0.0001). 
The majority of HPV (-) patients had cancers of the oral cavity (52%) whereas the majority of 
HPV (+) patients had cancer of the oropharynx (78%). The highest proportion of patients was 
stage IV with none or mild comorbidities regardless of HPV status, although more patients with 
HPV (+) tumors were diagnosed with stage IV tumors than those patients with HPV (-) tumors 
(77% vs 51%) primarily due to a higher frequency of patients with N2 neck disease that is so 
common in HPV related cancers.  Most HPV (-) patients were current smokers (48%) while HPV 
(+) patients had lower proportions of current (32%) smokers which were similar to the frequency 
of former (37%) and never (31%) smokers. Pack-years of cigarettes use only and all types of 
tobacco use were higher in HPV (-) patients (mean: 38.4 pack-years; 41.8 pack-years, 
respectively) compared to HPV (+) patients (29.9 pack-years; 29.6 pack-years, respectively; p-
value=0.02, p-value=0.005). Alcohol use, post treatment status and two year recurrence and 
survival rates were also significantly different by HPV status (Table 4.2).    
 
Patient Characteristics and Survival/Recurrence 
Kaplan-Meier curves with age categorized into quartiles revealed that the oldest quartile (Q4) 
had the worst probability of overall survival time (OST) compared to other ages (p<0.001), 
whereas there were similarly high probabilities of recurrence free survival time (RFT) for the 
two lowest quartiles of age and similarly low probabilities of RFT for the two highest quartiles of 
age, although these differences were not significant (p=0.09) (Figure 4.4). Patients who were 
HPV (-) had significantly poorer probabilities of both OST and RFT (p<0.001; p=0.001, 
respectively) (Figure 4.5). Smoking status was not significantly associated with either probability 
of OST or RFT, however trends revealed that never smokers had a better probability of OST than 
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former and current smokers (p=0.16). There was no difference in trend by smoking status with 
regard to probability of RFT (p=0.98) (Figure 4.6). Patients with HNSCC in their hypopharynx 
had the worst probabilities of OST and RFT compared to other disease sites. Following this, 
cancers of the larynx, oral cavity and oropharynx had increasing probabilities of OST and RFT 
(p<0.001; p<0.001, respectively) (Figure 4.7). There was no difference on probability of OST by 
stage of disease, although the trend showed earlier stages with slightly better probabilities 
(p=0.22). However, there was a clear separation in probability of RFT with the earlier stages 
clustering at around 0.85 compared the later stages clustered around 0.65 (p=0.05) (Figure 4.8). 
Patients with the highest ACE score denoting their comorbidity status had the lowest 
probabilities of OST and RFT. Probability of OST increased with decreasing ACE score 
(p<0.001) while probability of RFT was not significantly different for ACE scores 0-3 (p=0.10) 
(Figure 4.9).   
 
Tumor Methylation and Survival/Recurrence 
Quartiles of methylation show differential effects for survival and recurrence 
We categorized methylation by quartile within markers, with Q1 indicating the lowest 
quartile of methylation, and compared probabilities of overall and recurrence-free survival 
between quartiles (Figure 4.10). Both CD1A and NDN were significantly associated with OST in 
the total population. Methylation of CD1A in the lowest quartile (Q1) was associated with the 
lowest probability of OST whereas higher methylation in Q2, Q3 and Q4 clustered around a 
probability of OST of about 0.75 (p =0.007, Figure 4.10). Methylation of NDN in Q1 and Q3 
were associated with poor probability of OST compared to methylation in Q2 and Q4 (p-
value=0.001). CCNA1, DCC and NDN methylation were significantly associated with RFT in the 
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total population (Figure 4.11). CCNA1 and DCC depicted a U-shaped association where the 
lowest and highest quartiles, Q1 and Q4, had the lowest probabilities of RFT while the 
intermediate quartiles, Q2 and Q3, had similarly higher probabilities of RFT (p=0.04; p=0.01, 
respectively). NDN revealed a linear trend of increasing probability of RFT with increasing 
quartile (p=0.009).   
  
Quartiles of methylation across HPV status  
In HPV (+) patients, only CD1A was associated with OST. Low methylation of CD1A in 
Q1 had the lowest probability of OST compared to methylation in all other quartiles (p=0.002) 
(Figures 4.12 through 4.15). CCNA1 was associated with RFT in these patients.  High 
methylation in Q4 of CCNA1 had the worst probability of RFT, while methylation in Q2 had the 
best probability of RFT.  Methylation of this gene in Q1 and Q3 had similar probabilities of 
RFT.  
No markers were associated with probability of OST within HPV (-) patients, however, 
DCC methylation was significantly associated with probability of RFT. The trend of the quartiles 
of DCC methylation was nonlinear; intermediate levels of methylation in Q2 and Q3 were 
associated with higher probabilities of RFT while the highest and lowest quartiles were 
associated with the lowest probabilities of RFT (p=0.03) (Figures 4.12 through 4.15).  
 
 
NDN and CD1A methylation are novel markers of survival in HNSCC patients  
Univariate cox proportional hazards models for survival show that patients in the 25th 
percentile of methylation of CCNA1 had a 1.43 times higher odds of a death event than those in 
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the 75th percentile (95% CI: 1.04-1.96) (Table 4.3). Those with NDN methylation in the 25th 
percentile had almost twice the odds of a death event compared to those in the 75th percentile of 
methylation (95% CI: 1.42-2.71). Patients with both CD1A and DCC methylation in the 25th 
percentile had about 1.5 times higher odds of a death event than those in the 75th percentile of 
methylation (95% CI: 1.24-1.95; 95% CI: 1.10-1.98, respectively). Multivariable Cox 
proportional hazards models adjusting for site, stage, HPV status, age and comorbidity score 
showed that only significant associations of NDN and CD1A gene methylation with survival 
persisted in the total population (Table 4.3). Those with NDN methylation in the 25th percentile 
had a 1.6 times higher odds of a death event compared to those with methylation in the 75th 
percentile (95% CI: 1.13-2.39). Patients with CD1A methylation in the 25th percentile had a 1.3 
times higher odds of a death event compared to those with methylation in the 75th percentile 
upon adjustment (95% CI: 1.01-1.71).  These results indicate that for the total population, 
hypermethylation of NDN and CD1A are associated with better patient survival.  
Univariate cox proportional hazards models for recurrence reveal that patients with NDN 
methylation in the 25th percentile had a 1.6 times higher odds of a recurrence event than those in 
the 75th percentile (95% CI: 1.17-2.17) (Table 4.3). Those that have CD1A methylation and DCC 
in the 25th percentile had about 1.4 and 1.46 times higher odds of a recurrence event, 
respectively, as compared to those in the 75th percentile (95% CI: 1.08-1.73; 95% CI: 1.09-1.94). 
These associations did not persist upon adjustment for other variables. 
 
Novel methylation markers of survival and recurrence differ by HPV status 
To determine the extent to which HPV status may play a role in these findings, stratified 
Cox models were used to measure associations separately within each groups (Table 4.3). 
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Divergent associations were found in patients based on their HPV status. In HPV (+) patients, 
those with CD1A methylation in the 25th percentile had 3.34 times higher odds of a death event 
than those in the 75th percentile (95% CI: 1.88-5.93). The same patients had twice the odds of a 
recurrent event if they fell into the 25th percentile of CD1A methylation compared to the 75th 
percentile. These results indicate that hypermethylation of CD1A is associated with better 
survival and lower recurrence. Conversely, HPV (+) patients had a 0.31 times lower odds of a 
recurrent event comparing those in the 25th percentile to those in the 75th percentile of CCNA1 
methylation, indicating that hypomethylation of this gene is associated with lower recurrence.  
Within HPV (-) patients, NDN was significantly associated with survival. Patients with 
NDN methylation in the 25th percentile had 1.58 times higher odds of a death event compared to 
those in the 75th percentile of methylation (95% CI: 1.03-2.42), indicating hypermethylation of 
this gene is associated with better survival in HPV (-) patients only.   
 
Methylation Score indicates Survival and Recurrence 
Methylation score was used as a composite measurement of overall methylation status 
across all genes. A higher methylation score indicated tumors were methylated across all six 
genes.  When patients were separated out either by their composite score or by quartiles of 
distribution of composite scores, the proportion of HPV (-) patients decreased and the proportion 
of HPV (+) patients increased with increasing score/quartile (Figure 4.16a and 4.16b). These 
results indicate that HPV (+) tumors tend to be more methylated than HPV (-) tumors. 
Probability of OST was greatest for patients with the highest methylation scores and 
decreased with each score (Figure 4.16c). The same trend was seen for probability of RFT 
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(Figure 4.16d). These results indicate that overall methylation plays an important role in survival 
and recurrence.   
 
Tumor Methylation and Epidemiologic Characteristics 
Methylation is associated with epidemiologic characteristics 
Each methylation marker was significantly associated with age and disease site (Table 
4.4). HPV status was significantly associated with several markers. Methylation of CCNA1, 
NDN, CD1A, and DCC was higher while methylation of p16 was lower in HPV (+) tumors 
compared to HPV (-) tumors. Tobacco status was significantly associated with methylation of 
NDN, CD1A, and DCC (p=0.02; p<0.001; p=0.03, respectively).  Interestingly former smokers 
had lower methylation of these genes compared to never or current smokers. Methylation of 
NDN was higher in patients with higher stage tumors (p<0.001), while a trend for CCNA1 
methylation with stage was U-shaped, with higher methylation at stages I and IV (p=0.01). As 
comorbidity status increased, methylation of CD1A increased (p-value=0.006). Finally, 
methylation of NDN and DCC was significantly higher in males compared to females (p =0.003; 
p =0.002, respectively).   
Stratification by HPV status across these epidemiologic characteristics revealed HPV (+) 
tumors were hypermethylated across CCNA1, NDN, CD1A,  and  DCC, but hypomethylated in 
p16 as compared to HPV(-) tumors, regardless of epidemiological trait  (data not shown).  
 
DISCUSSION 
Changes in methylation patterns are one of the most frequent events in human tumors and 
epigenetic alterations have been increasingly recognized to play a role in the complex 
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mechanism of head and neck carcinogenesis. This study is the first to describe novel epigenetic 
alterations associated with survival in an unselected cohort of patients with HNSCC. DNA 
hypermethylation of NDN and CD1A was found to be significantly associated with improved 
overall survival time in the total study population. Stratification revealed major differences in 
these associations with survival by HPV status and identified novel methylation markers, 
including CCNA1, to be associated with recurrence in HPV (+) patients only. These unique 
discoveries raise significant new questions about why these specific epigenetic changes differ 
among biologically distinct subsets of HNSCC patients (HPV + versus HPV -) and whether these 
differences are in some mechanistic way linked to HPV status or are simply independent gene 
factors that are hypermethylated due to other unrelated reasons. 
NDN is a maternally imprinted gene that has monoallelic expression. It encodes necdin, a 
protein that interacts with p53 to induce cell cycle arrest47. Differences in Kaplan-Meier survival 
curves were seen across quartiles of NDN methylation, however the trend was not linear. Those 
in the lowest and third quartile of methylation had better survival than those in the second and 
fourth quartiles. Although necdin is a p53 target gene involved in cell growth arrest and found to 
be hypermethylated in cancers, it has recently been implicated to act more as a “switch”, 
promoting quiescence in the steady state but suppressing p53-dependent apoptosis in a stressful 
state47-50. The methylation trend by quartiles may reflect this “switch”-like behavior or could 
reflect some unknown biologic heterogeneity within the clinical characteristics of patients in 
these quartiles. Our adjusted Cox model analyses revealed hypermethylation of NDN was 
associated with better survival in the total population, and strongly, in HPV (-) patients 
specifically, where p53 status is a significant prognostic factor. Although precise mechanisms 
remain unknown, it would be anticipated that methylation would reduce NDN regulation of p53.  
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Previous literature has implicated necdin as a putative tumor suppressor; however, our results 
suggest that this multifunctional protein may be involved in other pathways that facilitate 
tumorigenesis, making hypermethylation of this gene beneficial for patient survival. 
CD1A encodes an immune protein responsible for presenting antigens by dendritic 
Langerhans cells to T lymphocytes such as natural killer cells. Infiltration of tumors by CD1a 
positive cells has been associated with aggressive behavior of oral cavity cancers51, 52.  The 
difference in Kaplan-Meier survival curves across quartiles of CD1A methylation showed that as 
methylation increased, probability of overall survival increased in the total population and in 
HPV (+) patients, specifically. This was validated in our adjusted Cox model analyses that 
revealed hypermethylation was associated with better overall survival for the total population 
and, for better survival and lower recurrence in HPV (+) patients specifically. Regulation of 
CD1A involves many factors associated with immune homeostasis in the tumor 
microenvironment, such as cytokine production53. Hypermethylation of this gene may be 
indicative of a failure in activation of immune suppressive myeloid cells in the tumor 
environment contributing to better patient survival rather than changes in this gene in the tumor 
cell component. Likewise, altered regulation of antigen presentation may induce chronic 
inflammatory responses that which may support immune mechanisms by this gene, which would 
be protective for survival.  This is particularly attractive speculation in view of differences with 
respect to HPV status in our study and recent correlations and important differences in 
immunologic status in the patient’s peripheral blood and tumor microenvironment according to 
HPV status54, 55. Patients with non-HPV related HNSCC tend to be significantly 
immunosuppressed and this immune suppression associated with worse outcomes. 
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Hypomethylation of CCNA1 was associated with lower odds of recurrent events in HPV 
(+) patients only. CCNA1 a cell cycle regulator that binds to retinoblastoma, E2F transcription 
factor and p21 family proteins to promote cell cycle progression.   This pathway is particularly 
important regulator of cell proliferation in HPV infection.  Our results suggest that decreased 
methylation of this cell cycle regulator is protective against recurrence events. Our findings are 
consistent with previous findings in HPV (+) HNSCC patients27, 56. Recently, a study found that 
HPV induced cyclin A1 overexpression could occur despite promoter hypermethylation, and this 
overexpression was associated with a lower recurrence rate56. 
Considering CD1A is an immune gene and CCNA1 is involved in response pathways to 
HPV infection, it is within reason that these genes would play a larger role in cancers with a viral 
etiology. On the other hand, NDN, which is involved in cell cycle regulation via p53 pathways, 
would more likely be involved in regulation of altered cell cycle pathways due to mutation 
events from chemical carcinogenesis.   Clearly, HPV (-) cancers are much more likely to harbor 
p53 mutations and inactivations while wild type p53 is a common finding in HPV (+) cancers 
that are associated with better outcomes.  It remains unclear if these significant associations with 
survival are due to treatment efficacy or reflect epigenetic variations due to co-morbidities or 
health behaviors.  In contrast to other reports from large outcome studies, there were not 
significant differences in survival outcomes with respect to comorbidities suggesting that the 
epigenetic changes more likely were reflective of differences in tumor biology rather than co-
morbidity.  Larger epigenetic studies of smoking, diet and comorbidities in our group are 
currently underway. 
Epidemiologic and clinical characteristics have generally been used to understand cancer 
phenotype, determine prognosis and inform treatment plans for patients. Epidemiologic factors 
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such as smoking history, nutrition, and comorbidity are well known significant prognostic factors 
for overall survival and indicate the importance of including such factors in studies of new 
molecular markers.  In the last decade, the clinical importance of better understanding tumor 
biology has emerged through validation of HPV status as a significant molecular predictor of 
patient survival and recurrence. Differences in patient outcomes according to HPV status are so 
dramatic that many investigators believe they reflect a new and unique phenotype that could 
justify significant de-intensification of therapy.  The novel methylation markers identified in this 
study offer new, specific, epigenetic molecular differences within the setting of the generalized 
hypermethylation phenotype associated with HPV status and warrant further investigation.  The 
findings support biological implications of epigenetic markers on patient survival and their 
potential usefulness in identifying unique subsets of patients with varied outcomes. Several 
markers show expected associations with patient characteristics.  
Hypomethylation of the immune marker, CD1A, is found in all HPV (-) tumors, but most 
hypomethylated in laryngeal tumors. Due to this gene’s involvement in immune function, it is 
not surprising to see that this gene is indicative of comorbidity status. HPV status and disease 
site are associated with methylation of p16, which encodes a cell cycle regulator and known 
tumor suppressor. Compared to HPV (+) tumors where this gene is expressed and the protein is 
inactivated, p16 is generally lost through chromosomal deletion, mutation or promoter 
hypermethylation in HPV (-) tumors57-59. This gene was hypermethylated in our HPV (-) patients 
and most methylated in oral cavity tumors compared with other sites, potentially as another 
mechanism by which to inactivate expression of this protein.  DCC encodes a tumor suppressor 
and methylation of this gene is associated with HPV status, site, tobacco status and gender. This 
gene is hypomethylated in HPV (-) patients and concurrently, is the least methylated in oral 
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cavity tumors. However, this gene, located on 18q is commonly found to deleted due to loss of 
heterozygosity (LOH) in HNSCC and therefore, may be inactivated through this pathway in 
HPV (-) patients60. It is hypermethylated in HPV (+) patients, which is consistent with previous 
literature in HNSCC, although many previous studies did not examine DCC methylation by HPV 
status32, 61-63.  CCNA1 was hypermethylated in our HPV (+) patients and was the most 
methylated in oropharyngeal tumors. This is consistent with previous findings in HPV (+) 
HNSCC patients27, 56. Recently, a study found that HPV induced cyclin A1 overexpression 
despite promoter hypermethylation, and this overexpression was associated with a lower 
recurrence rate56. CCNA1 was also associated with stage, specifically hypomethylation in stages 
II and III, perhaps indicating that this gene is important in progression of tumorigenesis. NDN 
was hypomethylated in HPV (-) tumors, but both oral cavity and larynx tumors were the least 
methylated sites. As stage increased, NDN methylation increased, indicating inhibition of this 
gene with progression of tumorigenesis. Promoter methylation of NDN was associated with the 
most epidemiological characteristics, making it a suitable marker to represent these traits. 
Overall, HPV (+) tumors tended to be more methylated as shown by composite 
methylation scores. Highly methylated tumors had a higher probability of OST compared to 
lowly methylated tumors, as expected. The association of methylation score with probability of 
RFT followed this trend as well, indicating that general methylation status of a tumor is 
indicative of survival and recurrence. 
Several of associations of methylation marks with characteristics such as stage, gender 
and tobacco status were novel. NDN, DCC, and CD1A all showed former smokers had lower 
methylation of these genes compared to never and current smokers. Because total pack years is 
inversely associated with these genes, perhaps the reason why former smokers stand out is 
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duration of exposure or exposure at an early age is integral in the initiation of processes that 
permits carcinogenesis.  
 
CONCLUSIONS 
Our cohort shows the expected associations established in previous literature, such as the 
relationships between stage, site, and HPV status with overall survival time and the expected 
population characteristics of a HNSCC cohort established by previous studies. For example, this 
study population consists of a majority of male patients, a higher number of cases diagnosed in 
later stages, larger proportion of HPV (-) tumors, and a mean age of about 60 years. Separation 
by HPV status reveals characteristics that are also expected from etiologic differences. HPV (+) 
patients are slightly younger, most HPV (-) tumors are in the oral cavity while most HPV (+) 
tumors are in the oropharynx, pack years are higher in HPV (-) patients and HPV (+) patients 
have longer recurrence free and overall survival times. These attributes provides assurance that 
the new associations discovered with this cohort are meaningful and can be extrapolated to the 
patient population. 
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Table	  4.1:	  Patient	  Clinical	  and	  Epidemiological	  Characteristics,	  N=346	  
Characteristic  N	   (%) Mean	  (std),	  range 
Age	  at	  Dx	  (years)    59.7	  (11.5),	  25-­‐93 
Gender Male 259 75%  
 Female 87 25%  
Cancer	  Site Larynx/Glottic 83 24%  
 Oral	  Cavity 126 36%  
 Oropharynx 125 36%  
 Hypopharynx 12 3%  
Cancer	  Stage I/Cis 47 14%  
 II 35 10%  
 III 52 15%  
 IV 212 61%  
Comorbidities	  (ACE) None 91 26%  
 Mild 158 46%  
 Moderate 70 20%  
 Severe 27 8%  
HPV	  status Positive 135	   39%  
 Negative 211	   61%  
Tobacco	  Use Current	  (within	  past	  12	  months) 145 42%  
 Former	  (quit	  >	  12	  months) 125 36%  
 Never 76 22%  
Pack	  Years,	  n=257 (cigs	  only)   35.6	  (30.0),	  0.1-­‐171.0 
Pack	  Years,	  n=264 (sum	  of	  cigs,	  cigars,	  pipe)	     37.7	  (33.3),	  0.07-­‐242.9 
Alcohol	  Use,	  n=244 Never 29 8%  
 Former	  (quit	  	  >12	  months) 227 66%  
 Current	  (within	  past	  12	  months) 90 26%  
Treatment,	  n=335 Surgery	  alone 67 20%  
 Radiation	  alone 34 10%  
 Surgery	  +	  Radiation 34 10%  
 Radiation	  +	  Chemotherapy 138 41%  
 Surgery	  +	  Radiation	  +	  
Chemotherapy 
39 12%  
 No	  Treatment	  prior	  to	  death 23 7%  
Persistent	  Diseasea  29	   8%  
     
Median	  Follow-­‐up	  for	  Survival  27.4	  
months 
  
Median	  Follow-­‐up	  for	  
Recurrence 
 24.0	  
months 
  
     
Recurrenceb	    81   
Death  78   
KM	  estimate	  2	  year	  RFTc   75%  
KM	  estimate	  2	  year	  OSTd   79%  
a).	  Disease	  considered	  persistent	  if	  patient	  never	  became	  disease	  free. 
b).	  Recurrence	  of	  the	  HNSCC	  in	  the	  primary,	  regional	  and/or	  a	  distant	  location.	  Patients	  whose	  disease	  never	  cleared	  after	  treatment	  are	  
included	  and	  considered	  recurrent	  with	  a	  recurrence	  time=1	  day.	  
c).	  OST=Overall	  Survival	  Time.	  Death	  from	  any	  cause	  considered	  an	  event.	  Overall	  survival	  time	  defined	  from	  date	  of	  diagnosis	  by	  UM	  
physician.	  
d).	  RFT=Recurrence	  Free	  Time	  defined	  as	  time	  from	  diagnosis	  to	  recurrence	  event	  or	  end	  of	  follow-­‐up.	  End	  of	  follow-­‐up	  is	  the	  last	  date	  where	  
patient	  was	  reviewed	  for	  recurrence.	  Patients	  whose	  disease	  never	  cleared	  after	  treatment	  are	  considered	  recurrent	  with	  a	  recurrence	  time=1	  
day.	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Table	  4.2:	  Patient	  Clinical	  and	  Epidemiological	  Characteristics	  by	  HPV	  Status,	  N=346	  
  HPV	  (–)  HPV	  (+)  HPV	  (-­‐) HPV	  (+)  
Characteristic  N (%	  )	  
among	  
HPV(-­‐) 
N (%)	  
among	  
HPV(+) 
Mean	  
(SD)	   
Mean	  
(SD)	   
p-­‐
value 
Age	  at	  Dx	  (years)  211  135  61.4	  
(12.3) 
57.0	  
(9.6) 
0.0002 
Gender Male 139 66% 120 89%   <0.001 
 Female 72 34% 15 11%    
Cancer	  Site Larynx/Glottic 72 34% 11 8%   <0.001 
 Oral	  Cavity 110 52% 16 12%    
 Oropharynx 20 9% 105 78%    
 Hypopharynx 9 4% 3 2%    
Cancer	  Stage I/Cis 36 17% 11 8%   <0.001 
 II 28 13% 7 5%    
 III 39 18% 13 10%    
 IV 108 51% 104 77%    
Comorbidities	  (ACE) None 41 19% 50 37%   0.001 
 Mild 99 47% 59 44%    
 Moderate 50 24% 20 15%    
 Severe 21 10% 6 4%    
Tobacco	  Use Current 
(within	  past	  12	  months) 
102 48% 43 32%   0.001 
 Former	   
(quit	  >	  12	  months) 
75 36% 50 37%    
 Never 34 16% 42 31%    
Pack	  Years,	  n=257 (cigs	  only)     38.4	  
(25.6) 
29.9	  
(28.8) 
0.02 
Pack	  Years,	  n=264 (cigs,	  cigars,	  pipe)	       41.8	  
(34.5) 
29.6	  
(29.4) 
0.005 
Alcohol	  Use,	  n=244 Current 
(within	  past	  12	  
months) 
63 30% 27 20%   0.01 
 Former	   
(quit	  >	  12	  months) 
126 60% 101 75%    
 Never 22 10% 7 5%    
Treatment,	  n=335 Surg	  alone 53 26% 14 11%   <0.001 
 Rad	  alone 23 11% 11 8%    
 Surg	  +	  Rad 30 15% 4 3%    
 Rad	  +	  Chemo 45 22% 93 70%    
 Surg	  +	  Rad	  +	  Chemo 29 14% 10 8%    
 No	  Treatment	  prior	  to	  
death 
22 11% 1 1%    
Post	  Treatment	  
Status 
Free	  of	  Disease 186	   88% 131 97%   0.004 
 Persistent	  Disease 25 12% 4 3%    
KM	  estimate	  	  	  	  	  	  	  	  	  	  2	  
year	  RFT 
  69%  84%   0.001 
KM	  estimate	  	  	  	  	  	  	  	  	  	  2	  
year	  OST 
  71%  91%   <0.001 
-­‐Percentages	  will	  not	  add	  to	  100%	  horizontally. 
%	  presented	  is	  proportion	  of	  clinical	  or	  epidemiological	  subgroup	  among	  HPV	  status	  category.	  
-­‐p-­‐values	  calculated	  by	  t-­‐test	  for	  continuous	  variables	  and	  chi-­‐square	  test	  for	  categorical	  variables.	  Log-­‐rank	  test	  used	  for	  KM	  analysis. 
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Table 4.3. Stratified Cox Proportional Hazards Analysis 
  Univariable HR 
(95% CI) Multivariable HR (95% CI) 
 Gene 
Methylation n
a Univariable HR (95% CI)c 
Multivariable 
HR                   
(95% CI)c,d 
Stratified Model 
Among HPV+c,e 
Stratified Model 
Among HPV-c,e 
O
ST
 
CCNA1b 341 1.43 (1.04, 1.96)* 1.13 (0.81, 1.59) 0.62 (0.25, 1.52) 1.25 (0.86, 1.81) 
NDN 346 1.96 (1.42, 2.71)*** 1.64 (1.13, 2.39)** 1.89 (0.87, 4.11) 1.58 (1.03, 2.42)* 
CD1Ab 342 1.55 (1.24, 1.95)*** 1.31 (1.01, 1.71)* 3.34 (1.88, 5.93)** 1.13 (0.84, 1.51) 
DCCb 344 1.48 (1.10, 1.98)** 1.30 (0.95, 1.78) 1.45 (0.59, 3.60) 1.28 (0.91, 1.79) 
p16b 343 1.005 (0.84, 1.18) 1.11 (0.93, 1.32) 0.76 (0.48, 1.19) 1.17 (0.97, 1.42) 
GADD45b 340 1.05 (0.80, 1.37) 0.88 (0.66, 1.17) 0.80 (0.43, 1.50) 0.91 (0.66, 1.25) 
R
FT
 
CCNA1b 334 1.06 (0.77, 1.47) 0.81 (0.57, 1.14) 0.31 (0.13, 0.74)* 0.96 (0.66, 1.42) 
NDN 339 1.59 (1.17, 2.17)** 1.40 (0.98,2.00) 1.42 (0.73, 2.78) 1.38 (0.90, 2.11) 
CD1Ab 335 1.37 (1.08, 1.73)** 1.12 (0.95, 1.62) 2.06 (1.21, 3.49)** 1.07 (0.79, 1.46) 
DCCb 337 1.45 (1.09, 1.94)* 1.32 (0.96, 1.83) 0.97 (0.40, 2.34) 1.37 (0.97, 1.94) 
p16b 336 0.92 (0.79, 1.08) 1.00 (0.84, 1.19) 0.91 (0.57, 1.46) 1.00 (0.84, 1.20) 
GADD45b 333 1.26 (0.97, 1.62) 1.12 (0.87, 1.46) 0.84 (0.49, 1.42) 1.23 (0.91, 1.66) 
* p<0.05, ** p<0.01, ***p<0.001. 
a) n=number of subjects in models  
b) Methylation values are log-transformed to adhere to normality assumption of Cox proportional hazards models. 
c) All methylation measurements standardized to interquartile ranges. HRs are interpreted as comparison between those with methylation in the 25th 
percentile compared to those with methylation in the 75th percentile 
d) ) Multivariable HR calculated from a multivariable Cox Proportional Hazards model after controlling for: age, HPV status, disease site, stage, and 
comorbidity score in the OST model and age, HPV status, disease site and stage in the RFT model. 
e) Multivariable HR (95% CI) calculated from a stratified multivariable Cox Proportional Hazards model. Models are stratified by HPV status to allow 
different baseline hazards for HPV+ and HPV- groups and also control for HPV status with a main effect and interaction with methylation marker. OST 
models control for: age, disease site, stage, and comorbidity score and RFT models control for: age, disease site and stage. 
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Table 4.4. Methylation Markers by Epidemiological Characteristics 
  CCNA1 NDN CD1A DCC p16 GADD45 
  
median 
(range) p 
median 
(range) p 
 median 
(range) p 
median 
(range) p 
 median 
(range) p 
median 
(range) p 
Age 26 (3, 90.5) <0.001 44.2 (10.8, 84.9) <0.001 69.8 (21.4, 93.9) 
<0.00
1 33.0 (3.0, 85.8) 
<0.00
1 2.3 (0, 70.1) <0.001 1.4 (0, 16) <0.001 
HPV                         
Positive 33.3 (3.0, 76.0) <0.001 52.7 (14.0, 84.9) <0.001 77.6 (25.1, 93.9) <0.001 
44.7 (3.1, 85.8) <0.00
1 
1.9 (0, 59.8) <0.001 1.4 (0.4, 3.9) 0.8 Negative 20.9 (5.5, 90.5) 40.0 (10.8, 80.3) 65.4 (21.4 (92.2) 26.0 (3.0, 83.3) 2.5 (0, 70.1) 1.4 (0, 16) 
Tobacco                         
Current 25.5 (6.3, 76.0) 
0.8 
45.0 (10.8, 84.9) 
0.02 
69.5 (25.1, 91.7) 
<0.00
1 
39.5 (4.2, 83.3) 
0.03 
2.2 (0, 70.1) 
0.7 
1.4 (0, 16) 
0.5 Former 25.6 (6.8, 77.0) 42.2 (11.2, 80.3) 64.4 (21.4, 90.0) 29.3 (3.0, 85.8) 2.4 (0, 46.6) 1.4 (0, 3.9) 
Never 26.6 (3, 90.5) 46.4 (14.0, 84.2) 79.7 (47.2, 93.9) 35.7 (3.1, 79.8) 2.2 (0, 26.9) 1.5 (0.3, 3.7) 
Site                         
Larynx 24.5 (8.0, 90.5) 
<0.001 
41.2 (11.2, 84.9) 
<0.001 
56.2 (21.6, 92.2) 
<0.00
1 
26.3 (3.1, 83.3) 
<0.00
1 
2.4 (0, 51.8) 
<0.001 
1.4 (0, 3.9) 
0.02 
Oral Cavity 22.0 (5.5, 77.0) 40.0 (10.8, 62.8) 70.6 (21.4, 90.2) 28.4 (3.0, 67.2) 2.6 (0, 70.1) 1.4 (0, 16.0) 
Oropharyn
x 32.3 (3.0, 76.0) 52.7 (21.8, 84.2) 77.5 (21.6, 93.9) 42.5 (6.1, 81.6) 2.0 (0, 39.9) 1.4 (0.4, 3.9) 
Hypophary
nx 15.6 (9.0, 64.0) 44.2 (17.2, 91.0) 60.5 (25.1, 90.6) 54.5 (12.3, 85.8) 2.6 90, 59.8) 1.1 (0, 1.6) 
Stage                         
I/Cis 27.5 (11.8, 77.0) 
0.01 
38.6 (11.2, 80.3) 
<0.001 
68.1 (30.3, 89.4) 
0.8 
26.7 (3.0, 67.2) 
0.1 
2.5 (0, 39.0) 
0.1 
1.3 (0, 3.5) 
0.3 II 22.4 (12, 74.3) 41.2 (17.2, 84.2) 68.8 (21.6, 88.3) 40.8 (7.9, 83.3) 2.3 (0, 59.8) 1.4 (0.6, 4.6) III 21.3 (6.8, 61.3) 40.4 (15.3, 69.7) 71.2 (21.4, 90.2) 28.8 (3.9, 75.1) 2.6 (0, 70.1) 1.5 (0, 16.0) 
IV 27.6 (3.0, 90.5) 46.8 (10.8, 84.9) 70.5 (21.6, 93.9) 35.9 (3.1, 85.8) 2.2 (0, 51.8) 1.4 (0, 3.9) 
Comorbidit
ies                         
None 29.5 (6.3, 74.3) 
0.4 
46.0 (20.2, 84.2) 
0.3 
74.8 (32.4, 93.9) 
0.006 
33.1 (5.6, 75.2) 
0.6 
2.5 (0, 39.9) 
0.4 
1.5 (0.4, 4.6) 
0.1 Mild 25.5 (3.0, 77.0) 43.3 (10.8, 84.9) 69.5 (21.6, 92.0) 35.4 (3.0, 85.8) 2.2 (0, 70.1) 1.4 (0, 16.0) Moderate 23.0 (6.8, 90.5) 44.0 (15.0, 79.3) 69.2 (21.4, 92.2) 29.8 (3.5, 79.8) 2.2 (0, 59.8) 1.3 (0, 3.9) 
Severe 30.5 (13.5,63.3) 44.6 (11.2, 80.3) 65.4 (21.6, 85.1) 43.0 (6.2, 83.3) 1.8 (0, 51.8) 1.2 (0, 3.9) 
Gender                         
Male 26.5 (3.0, 90.5) 
0.2 
45.6 (13.0, 84.9) 
0.003 
69.9 (21.4, 93.9) 
0.4 
36.1 (3.1, 85.8) 
0.002 
2.3 (0, 70.1) 
0.9 
1.4 (0, 3.9) 
0.5 
Female 23.8 (6.3, 77.0) 
40.5 (10.8, 
68.9) 69.5 (21.6, 91.7) 25.4 (3.0, 75.1) 2.1 (0, 46.6) 
1.4 (0, 
16.0) 
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Figure 4.1. Tumor sites of the head and neck 
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Figure 4.2 Five-year survival by year of diagnosis and tumor site 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure adapted from the National Cancer Institute 
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Figure 4.3. Distinct clinicopathology of HPV-positive and HPV-negative HNSCCs  
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Figure 4.4. Age is significantly associated with survival. a) The oldest patients have the poorest probability of OST compared to ages in all other 
quartiles; b) Probability of RFT increases with decreasing quartiles of age 
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Figure 4.5. HPV(+) patients have significantly better prognosis compared to HPV (-) patients. a) HPV+ patients have a significantly higher 
probability of OST; b) HPV(+) patients have a significantly higher probability of RFT 
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Figure 4.6. Smoking status is not associated with survival or recurrence. a) Never smokers have the best probability of OST, but smoking is not 
significantly associated with OST; b) Probability of RFT is similar across smoking statuses 
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Figure 4.7. Disease site is significantly associated with prognosis. a) Patients with tumors in the hypopharynx have the worst probability of OST 
while patients with sites of larynx, oral cavity and oropharynx have increasing probabilities of OST; b) Probabilities of RFT follow the same 
trends as OST 
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Figure 4.8. Disease stage is not associated with prognosis. a)There is no separation of curves across stage of probability of OST; b) There is a 
slight separation of curves for probability of RFT, with stages 1 and 2 having slightly better probabilites 
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Figure 4.9. Comorbidity score is associated with survival only. a) Probability of OST significantly decreases with increasing score; b) Similar 
trends are seen for RFT as for OST, but these are not significant 
 
 
 
 
 
129	  
	  
Figure 4.10. Probability of overall survival by quartiles of methylation. CD1A and NDN are significantly 
associated with probability of OST. The lowest quartile (Q1) of CD1A methylation has the worst 
probability while the rest of quartiles cluster around a probability of 0.75 (b); Q1 and Q3 of NDN have the 
lowest probabilities of OS, while Q2 and Q4 have the highest 
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Figure 4.11. Probability of recurrence free survival by quartiles of methylation. CCNA1, NDN and DCC 
re all significantly associated with probability of RFT; Quartiles of CCNA1 (a) and DCC (d) are 
associated with probability of RFT in a U-shaped manner where the lowest and highest quartiles have the 
lowest probabilities and the intermediate quartiles have high probabilities of RFT; Probability of RFT 
increases with increasing quartile of NDN methylation (c) 
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Figure 4.12. Association of CCNA1, CD1A, and NDN with survival, stratified by HPV status.  CD1A is significantly associated with probability of 
OST in HPV(+) patients only. Low methylation of CD1A in Q1 has the lowest probability of OST compared to all other quartiles (d); No other 
significant associations are seen for these genes 
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Figure 4.13. Association of DCC, p16, and GADD45 with survival, stratified by HPV status. These markers re not significantly associated with 
probability of OST by HPV status
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Figure 4.14. Association of CCNA1, CD1A, and NDN with recurrence, stratified by HPV status. CCNA1 is associated with probability of RFT in 
HPV (+) patients. CCNA1 methylation in Q4 has the worst probability, Q2 has the best probability and Q1 and Q3 had similar probabilities of RFT 
(b) 
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Figure 4.15. Association of DCC, p16, and GADD45 with recurrence, stratified by HPV status. DCC methylation is significantly associated with 
probability of RFT; The trend of quartiles of DCC methylation are non-linear;  intermediate quartiles, Q2 and Q3, have higher probabilities while 
Q1 and Q4 have the lowest probabilities of RFT
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Figure 4.16. Distribution and association of methylation score with survival and recurrence. Number of 
HPV(-) patients decreases while number of HPV(+) patients increases as methylation score increases (a) 
and as quartile of methylation score increases (b); Probabilities of OST and RFT significantly decrease as 
methylation scores decrease (c, d) 
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CHAPTER 5 
Public Health Implications 
 
The work presented in this dissertation provides key findings that have immediate 
implications in the field of public health. Additionally, it provides a basis for future work for 
continuous research on environmental influences on cancer through its long-term implications. 
 
BREAST CANCER IN THAILAND 
 Cancer is a leading cause of death worldwide. Sixty percent of cancer incidence occurs in 
low and middle income countries (LMICs)1. With the burden of cancer shifting to LMICs, it is 
necessary to provide data on incidence trends to support evidence-based implementation of 
strategies for cancer prevention, early detection of cancer and management. 
This study used cancer registry data from Songkhla, Thailand to identify and forecast 
incidence trends for female breast cancer by age group.  
 
Immediate Public Health Implications 
 This work analyzes female breast cancer in southern Thailand providing evidence of late staging 
of cancers and increased incidence in women at or above age 50. Characterization of incidence 
trends reveals that both period and cohort effects are significant contributors indicating that there 
may be separate types of risk factors that are contributing to incidence. Certain risk factors may 
affect younger generations more, whereas others affect older generations more. Some risk factors 
that are differential 
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between younger and older women include parity, adherence to self-breast examinations, 
changes in diet, age at first menarche, older ages at first birth, post-menopausal obesity, alcohol 
consumption, exogenous estrogen, and sexual behavior2.  Some of these may be exacerbated 
during certain time periods contributing to period effects of the incident trend, while others 
represent generational lifestyle changes. The level of contribution of these risk factors are 
shifting as this country undergoes an epidemiological transition from a culturally traditional 
lifestyle to a more western lifestyle. This study provides characterization of female breast cancer 
rates in a region-specific manner, which is important as lifestyle factors vary dramatically by 
region. Additionally, it provides contextual evidence to examine the role of risk factors that 
change across generations and during specific time periods as lifestyle patterns change due to 
economic development in this region. 
 
Long-Term Public Health Implications  
This analysis consists of female breast cancer in Songkhla province only. However, the 
Thai NCI has established that breast cancer is the leading cancer in women nationally. Because 
there are several cancer registries across Thailand, results from this study can be combined with 
information from other registries to understand the incidence trends of female breast cancer 
across Thailand. Additionally, registry data from each region can be analyzed separately using 
this methodology to determine the types of effects that contribute to the region-specific incidence 
trends, providing a basis to determine differential risk factors by region. Careful characterization 
of cancer trends will provide the basis for future research to identify important risk factors, 
design interventions, and create prevention strategies. 
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CADMIUM IN THAILAND 
Heavy metals have long been associated with carcinogenesis. Much of the evidence 
comes from industrial or occupational settings where exposures tend to be acute. However, 
environmental exposures to heavy metals also exist, although the exposure tends to be 
chronically low and may induce distinct pathways of carcinogenesis3.  This study measured the 
association between environmental cadmium exposure and methylation markers in the highly 
exposed population of Mae Sot, Thailand. 
Additionally, renal dysfunction was used as a proxy for disease since the process of 
carcinogenesis takes a long time to develop. Currently, the mechanism by which cadmium exerts 
its toxic effects is unknown. In vitro and animal studies have implicated the involvement of 
certain genes, but this has not been evaluated in human population in relevant doses.  
 
Immediate Public Health Implications 
This study takes advantage of a unique population with a wide range of environmental exposure 
to cadmium, to validate methylation markers that have been previously implicated in 
mechanisms of Cd toxicity. Much of what we know about molecular mechanisms of Cd toxicity 
comes from in vitro and animal studies. To date, few studies considering molecular events have 
been conducted in human populations. The results from this study validate specific methylation 
markers in human populations in relation to both cadmium exposure and renal dysfunction, a 
known health outcome of cadmium exposure. Importantly, these results confirm sex-specific 
differences on a molecular level. It has long been known that cadmium affects women differently 
from men. This is seen primarily from the sex-ratio of itai-itai disease patients and incidence 
rates of adverse health effects in women compared to men in response to cadmium exposure4-7 . 
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The presence of molecular differences implicates distinct events that occur to generate sex-
specific health outcomes.  
 
Long-Term Public Health Implications  
This work provides a basis for future studies to examine epigenetic changes in particular 
pathways as potential molecular mechanisms of cadmium toxicity leading to carcinogenesis. The 
toxicokinetics of cadmium indicate renal dysfunction is the direct health effect linked to 
cadmium exposure. Additionally, the levels of exposure known to induce renal dysfunction have 
also been associated with cancer incidence. Several methylation markers were associated only 
with cadmium exposure, offering potential mechanisms a variety of downstream health effects. 
Other methylation markers were associated with both cadmium exposure and renal dysfunction, 
implicating that methylation of these markers fall along the pathway of exposure and disease. It 
will be necessary to validate these novel biomarkers of exposure in cohorts with cancerous 
outcomes. The differential methylation markers by sex provide evidence that future interventions 
should be targeted at men and women separately, focusing on sex-specific behaviors and 
exposures.  
 
HEAD AND NECK CANCER IN THE U.S. 
Cancer is a heterogeneous disease and insufficient understanding has led to little improvement in 
survival for several types of cancer, including HNSCC. Biomarkers of diseases associated with 
survival play an important role in addressing high mortality rates of cancer. This study 
determined the association between methylation markers and patient survival by HPV status in 
HNSCC.  
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Immediate Public Health Implications 
Currently, subsets of HNSCC are based on HPV status, a known biological factor that 
contributes to etiology of this cancer. HPV (+) patients have a prognostic advantage in terms of 
survival, although it is unclear whether this is due to tumor biology, epidemiologic 
characteristics, or a combination of the two. However, even within the HPV+ group, there is a 
good deal of heterogeneity in survival time, with up to 20% progressing with distant metastases. 
This study identifies novel biological factors that are associated with survival and recurrence and 
exhibit differential methylation by HPV status and epidemiological characteristics.  These 
biomarkers highlight differences in tumor biology that contribute to differential prognosis 
supporting biological implications of epigenetic markers on patient survival. 
 
Long-Term Public Health Implications  
Differences in patient outcomes according to HPV status are so dramatic that many investigators 
believe they reflect a new and unique phenotype that could justify significant de-intensification 
of therapy.   Methylation markers may incorporate epidemiologic characteristics with tumor 
biology and therefore are useful in understanding survival differences by HN subtypes. The 
novel methylation markers identified in this study offer new, specific, epigenetic molecular 
differences within the setting of the generalized hypermethylation phenotype associated with 
HPV status and warrant further investigation. These markers offer potential usefulness in 
identifying unique subsets of patients with varied outcomes, providing an opportunity for 
targeted, personalized care. 
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CHAPTER 6 
Conclusions 
 
This thesis highlights studies that are essential in understanding the trajectory of human 
environmental exposures inducing and progressing carcinogenic events, both on an 
epidemiological and a molecular basis.  
The study in chapter two focused on the changing environment and induction of cancer, 
measured epidemiologically through the use of incidence rates from population-based cancer 
registries. There are many known risk factors for breast cancer, but this health burden is rising 
the fastest in LMICs. Thailand is one country undergoing an epidemiologic transition in lifespan 
and lifestyle characteristics combined with a shift from infectious to chronic diseases. This shift 
in risk profiles of southern Thai women deems it necessary to focus on early detection and 
awareness of breast cancer. In this study, female breast cancer incidence trends were 
characterized to be influenced by both period and cohort effects, implicating risk factors 
associated with birth year and lifestyle/behavioral changes in more recent years. Additionally, 
keeping the current healthcare infrastructure constant, comparative modeling illustrated that 
these trends would continue to increase for women of all ages, although trends for women ages 
50 and up would accelerate at a much faster rate by 2029. These results provide a basis for future 
health care planning, focusing on potential integration of mammography or other preventive 
screening techniques into the universal health care system.  Although breast self-examination is 
practiced, compliance is highest only in younger females, leaving the older female population at 
risk. Inclusion of mammography into universal healthcare would promote preventative care and 
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although incidence rates would increase due to capture of more cases, cancers will be staged 
earlier allowing for more effective treatment and management.  
A strength of this study is that it is the first one to characterize breast cancer trends in a 
specific region of Thailand. Lifestyle factors vary dramatically by region and likely have 
differential effects on incidence rates, making it necessary to study trends in a region-specific 
manner. Additionally, cancer trends are characterized separately for low and high risk groups in 
terms of menopausal status, allowing for evidence to be used in interventions targeted at specific 
age groups. Although the registry data are limited due to the lack of information on biomarkers, 
religion and other lifestyle characteristics, this is an inherent limitation as, to date, there has not 
been comprehensive data collection at the population-level. Regardless, this study provides the 
first in-depth look at the epidemiology of breast cancer in southern Thailand. Because of the 
changing risk profile of the women in this region, these findings need to be extended to 
characterize the population in terms of diet, lifestyle and genetic factors to direct strategies aimed 
at controlling the burden of breast cancer in Thailand. 
Chapter three was centered on environmental exposure to a known carcinogen and the 
induction of disease, measured molecularly through the use of epigenetic markers as biomarkers 
of effect. Cadmium was found to be associated with DNA methylation levels of important 
candidate genes that have been previously shown from in vitro and animal studies to be involved 
in mechanisms of toxicity. Specifically, cadmium was associated with DNA methylation 
differentially by sex. These biomarkers of effect were also associated with renal biomarkers 
indicative of renal dysfunction.  The process of carcinogenesis takes years to develop, so renal 
dysfunction was used as a proxy as this is a known health effect of cadmium and the same levels 
of exposure that have been shown to induce renal dysfunction have also been associated with 
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cancer incidence.  Urinary cadmium levels, indicative of body burden of this exposure, were 
associated with biomarkers of effect that fall along the pathways of cadmium toxicity, although 
these marks differed by sex, indicating that cadmium toxicity may occur through differential 
mechanisms in males compared to females. 
Strengths of this study include the use of a population with a wide range of relevant 
cadmium levels and extensively characterized methylation biomarkers.  This is the first study 
able to look at such ranges within the context of DNA methylation in a population-based study. 
However, this cross-sectional study was limited in the amount of information provided as we did 
not have a part in the creation of the questionnaire and the survey had already been completed by 
the time these analyses took place. It would have been useful to have measurements on diet, 
body burden of other heavy metals that coexist with environmental cadmium or longitudinal data 
that would have allowed for measurement of cancerous outcomes. Dietary information would 
have been useful to understand the amount of cadmium ingested along with other food items that 
may affect metabolism or biotransformation of cadmium. Other heavy metals such as lead, 
nickel, lead and copper, are commonly found with cadmium in the environment and may work 
synergistically to induce adverse health outcomes. Longitudinal data would have allowed for 
measurement of cancer incidence, although this limitation was addressed by using renal 
dysfunction as a proxy since Cd exposure levels associated with kidney effects and various 
cancers are similar. Finally, methylation was measured in circulating cells of the blood and 
therefore, the direct effects of Cd on DNA methylation may not be extrapolated to relevant 
tissues, such as the kidneys and liver. Nevertheless, the results from this study are important in 
recognizing that differential mechanisms of cadmium toxicity may come into play depending on 
sex. This has been previously alluded to with the recognition that women tend to sequester larger 
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amounts of cadmium and suffer more from osteoporosis than men. Additionally, the past 
outbreak of itai-itai disease from environmental cadmium exposure in Japan had only 3 out of 
195 patients that were male, suggesting that cadmium toxicity affects females differently than 
males. In spite of this, few studies have looked at sex-specific incidence rates of cancer with 
regards to environmental cadmium exposure, highlighting a need to examine cancer outcomes in 
this way.  
Chapter four discussed prognostic markers, found in diagnosed cancer patients, which 
indicate overall patient survival and recurrence free survival from head and neck squamous cell 
carcinoma (HNSCC). The 5-year survival rate has remained at about 50-60% for the past decade. 
Although HPV-associated cancers are indicative of improved prognosis, there is still 
heterogeneity in survival time, highlighting a need for prognostic markers of survival patients 
related to tumor biology and epidemiologic characteristics. Several epigenetic marks were found 
to be associated with survival and recurrence, both overall and within HPV subsets of HNSCC. 
These discoveries are novel findings as they have not previously been associated with prognosis 
and offer new, specific, epigenetic molecular differences within the setting of the generalized 
hypermethylation phenotype associated with HPV status. 
A limitation of this study is that there is no measurement on the persistence of these 
epigenetic marks. As this is a cross-sectional study using tumor tissue from previously untreated 
patients, specimens are difficult to come by and radiation/chemotherapy treatments begin after 
surgery. Additionally, diet, which is known to influence DNA methylation patterns and have 
been associated with survival in HNSCC patients, is not included in this study. Combining 
methylation data with diet information would be useful in determining if these DNA methylation 
marks are truly indicative of prognosis. A strength of this study is the use of a well-characterized, 
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unselected cohort of HNSCC patients at the University of Michigan, with extensive 
epidemiologic, clinical and survival information, treated by a single group of clinicians with a 
homogenous treatment approach.  This cohort shows the expected associations established in 
previous literature, such as the relationships between stage, site and HPV status with overall 
survival time, and the expected population characteristics of a HNSCC cohort established by 
previous studies, providing assurance that the new associations discovered with this cohort are 
meaningful and can be extrapolated to the patient population. The findings from this study 
support biological implications of epigenetic markers on patient survival and their potential 
usefulness in identifying unique subsets of patients with varied outcomes. 
The changing environment has a profound effect on human health worldwide. Both 
epidemiological and molecular studies are needed to address the rising global cancer burden that 
will particularly affect low- and middle-income countries (LMICs). The work presented here 
addresses this issue using three studies that cover the spectrum of environmentally influenced 
cancer, from induction to progression to final prognosis. Findings from this work are crucial in 
understanding the evolution of disease and in providing evidence that can be used in prevention, 
healthcare planning and clinical treatment. 
